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Does Patient Dementia Limit the Use of Cardiac Catheterization in
ST-Elevated Myocardial Infarction?

Marianne Chanti-Ketterl

ABSTRACT

Regardless of age or mental capacity, percutaneous coronary intervention
(PCI) is the first line of treatment for ST-elevated myocardial infarction
(STEMI). This study evaluates the disparities in the use of diagnostic cardiac
catheterization and PCI in STEMI patients with dementia. A retrospective
analysis was performed of Florida‟s comprehensive inpatient surveillance
system for the years 2006-2007 with admission diagnosis of STEMI. Logistic
regression analysis was used to identify disparities in the use of intervention
among all STEMI patients. A total of 8,331 STEMI patients met the inclusion
criteria. Of these, 77% were catheterized and of these 67% received PCI. A
total of 605 (7.3%) were demented. Patients with dementia were less likely
to be catheterized (RR 0.4, 95% CI 0.3-0.5) and less likely to receive PCI
within 24 hours (RR 0.5, 95% CI 0.4-0.6). This study concludes that STEMI
patients with dementia were much less likely to receive cardiovascular
interventions.
x

CHAPTER ONE
INTRODUCTION

According to the American Heart Association (AHA), an American will suffer
some form of coronary event every 25 seconds. The annual incidence of
myocardial infarctions (MI) in the United States for 2009 is projected to be
610,000 new attacks and 325,000 recurrent ones(3). The AHA Get With the
Guidelines estimates that about 32% of these MIs are ST-Elevated
Myocardial Infarctions (STEMIs)(3); about one third of these will result in
death within 24 hours of the onset of symptoms(4).

Although the trend in the number of people afflicted by myocardial infarction
has steadily decreased in recent years, due in part to advancements in
technology and treatment such as the use of Percutaneous Coronary
Intervention (PCI), the disparities in care for certain groups have not
improved. Studies still report that minorities, the elderly, and women with
heart disease are undertreated, less likely to receive PCI, and are more likely
to die during hospitalization(3, 5-7).
1

The aging of the population and the rising number of seniors suffering from
chronic degenerative diseases have major impacts on public health. The
Centers for Disease Control and Prevention estimate that 80% of older
Americans are living today with at least one chronic illness(6). One such
growing problem is dementia; a syndrome characterized by progressive
mental deterioration.

The World Alzheimer Report conducted a systematic review of 147 studies
globally and estimated that in the year 2010, 35.6 million people will suffer
from dementia worldwide(8). An earlier estimate by Plassman et al. from the
Aging, Demographics, and Memory Study (ADAMS) sample, a subcohort from
the Health and Retirement Study (HRS) of 856 individuals 70 years or older
from different regions in the United States, estimated the prevalence of
dementia among people older than 71 at 13.9% which translates to about
3.4 million people in the United States in 2002 and approximately 9.7%
prevalence for Alzheimer‟s type dementia for those over 71 years of age for
that year(9). However, a report published in 2009 by the Alzheimer‟s
Association suggests that 5.3 million Americans have Alzheimer‟s dementia
(AD)(10). Studies show that the prevalence of dementia doubles with every
5-year increase after 65 years of age(6, 8, 11). According to the Alzheimer‟s
Association report for 2009, from the year 2000 to 2006 the death
2

percentage attributable to Alzheimer‟s disease increased 46.1% in contrast to
heart disease, which decreased 11.1%(12).
The health cost of dementia is profound; it not only affects the patient but
the entire family and society as well. The economic worldwide expenditure
for dementia is $315 billion(8). In 2005, the direct cost to Medicare and
Medicaid for Alzheimer‟s disease alone escalated to $148 billion in the United
States(10). The estimated total cost of cardiovascular disease for 2009 was
$475.3 billion dollars(3); it seems evident that this is a public health crisis.
Consequently it is imperative to recognize the impact of these two diseases
combined and acknowledge the health and socio-economic cost to future
generations.

1.1 Main Aim of the Study
The magnitude of this problem is noteworthy, the increased risk of disability
from the combination of dementia and heart disease is large, and the health
care costs associated with both pathologies are worrisome for this and future
generations. This alarming health care problem prompted me to perform a
retrospective cohort analysis of the inpatient surveillance data from Florida to
determine if there is disparity in the use of diagnostic cardiac catheterization
for ST-Myocardial Infarction patients with a diagnosis of dementia versus
patients without a diagnosis of dementia after controlling for the following
patient and hospital factors: age; gender; ethnicity; zip code SES; year of
3

hospital admission; hour of arrival at the emergency department; source of
admission; principal payer and the following comorbidities: hypertension
(HTN), diabetes mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP),
obesity, smoking history (SMK), depression (DEP), end stage renal disease
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD) and alcohol abuse (OH).

1.2 Secondary Aims of the Study
1. To determine if there is a difference in PCI use between STEMI patients
with and without dementia who underwent cardiac catheterization after
controlling for the following patient and hospital factors: age; gender;
ethnicity; zip code SES; year of hospital admission; hour of arrival at the
emergency department; source of admission; principal payer and the
following comorbidities: hypertension (HTN), diabetes mellitus type 2
(DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney
disease (CKD), congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD) and alcohol abuse(OH).

2. To ascertain if there is a disparity of CABG use between STEMI patients
with and without dementia who underwent cardiac catheterization after
controlling for the following patient and hospital factors: age; gender;
4

ethnicity; zip code SES; year of hospital admission; hour of arrival at the
emergency department; source of admission; principal payer and the
following comorbidities: hypertension (HTN), diabetes mellitus type 2
(DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney
disease (CKD), congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD) and chronic alcohol abuse (OH).

3. To determine if there is a difference between the days to procedure (PCI
or CABG) for STEMI patients with and without dementia after controlling
for the following patient and hospital factors: age; gender; ethnicity; zip
code SES; year of hospital admission; hour of arrival at the emergency
department; source of admission; principal payer and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

4. To identify if having dementia affects the length of hospital stay for STEMI
patients after controlling for the following patient and hospital factors:
age; gender; ethnicity; zip code SES; year of hospital admission; hour of
arrival at the emergency department; source of admission; principal
5

payer and the following comorbidities: hypertension (HTN), diabetes
mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity,
smoking history (SMK), depression (DEP), end stage renal disease
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD) and chronic alcohol abuse
(OH).

Other factors that will be considered in the analyses include, hospital PCI
volume, in-hospital mortality, day of the week admitted, socio-economic
status, and any additional procedures that were performed during the
hospital stay.

This study was approved and exempted by the Institutional Review Board of
the University of South Florida on March 19th, 2010.

6

CHAPTER TWO
LITERA TURE R EVI EW

2.1 Descriptive Epidemiology of Dementia
Dementia is a chronic syndrome caused by a variety of pathologies and
conditions that involve the loss of mental capacity, with emphasis in memory
loss, severe enough to interfere with activities of daily living (10, 13, 14). It
includes memory, learning, orientation, language, comprehension and
judgment deterioration (8, 13, 14). When mild problems in these areas are
observed that do not interfere with daily life, the syndrome is referred to as
Mild Cognitive Impairment (MCI)(10). Some cases of MCI develop into
dementia and others do not; the reason for this is still not clear.

Recent studies approximate the prevalence of dementia in the United States
at about 13%(9, 10, 12). Studies also confirmed that this prevalence doubles
with every 5-year increase in age after age 65 (6, 8, 11, 13). The most
frequent type of dementia accounting for 80% of cases is Alzheimer‟s disease
(AD) with approximately 5.3 million Americans affected in 2010(12). The
Alzheimer‟s Association estimates that there‟s a new case of Alzheimer‟s in
7

the United States every 70 seconds(10) and that by the year 2050 this
estimate will have decreased to every 33 seconds(12).

Data from the CDC(15), reported the annual crude death rate of AD at 24.2
per 100,000 population in 2006, the same figure as diabetes mellitus. The
age-adjusted death rate for AD that year was 22.6 per 100,000 U.S.
standard population(15), a decrease of 1.3% from 2005 to 2006, making it
the seventh leading cause of death in the United States in 2006(15, 16).
According to Heron et al., in 2006 there were 72,432 deaths caused by
Alzheimer‟s disease, which constituted 3% of the total deaths in the United
States(15, 16). However underreporting AD on death certificates as cause of
death has been well documented, and more recent estimates suggest that
AD is the fifth leading cause of death in Americans aged 65 and older(10).

A meta-analysis study conducted by Alzheimer‟s Disease International
estimates that the prevalence of dementia in North America will increase 63
percent over the next twenty years, mainly due to the demographic shift.
Current estimates indicate that there are currently 35.6(8) million people
worldwide with this syndrome and of these 5.3(10) million with Alzheimer‟s
dementia in the United States, of which 5.1(10) million are over the age of
65. Two hundred thousand people younger than 65 have what scientists call
early onset Alzheimer‟s(10) and the rest are late onset dementia.
8

2.1.1 Pathology of Alzheimer Type Dementia
Even though it is known that the underlying cause of most dementias,
including AD is genetic, the exact mechanisms are still unknown. Dementia is
now known to be the result of a combination of pathological disruptions in
the brain that end up injuring brain cells, making them loose their functional
capacity. Most scientists agree that the pathology of AD may have multiple
causes, with some factors yet to be discovered. Among the most commonly
understood pathological risk factors to date are genetic, inflammation,
oxidative stress, hormonal changes and head injury(17, 18).

Established characteristics of the Alzheimer‟s brain as observed in
pathological studies are amyloid (neuritic) plaques, neurofibrillary tangles
and loss of connection between the cells which lead to cell death(13, 17, 1921). Neuritic plaques are composed mainly of deposits of beta-amyloid
protein, which can lead to increased microglia and reactive astrocytes(21);
while neurofibrillary tangles, or intraneuronal bundles, are composed mainly
of a protein called tau, which causes a disruption in the neuron‟s transport
system leading it to fail(13).

Few epidemiological studies have focused on the neuropathology of
dementia(21, 22). A recent study by Matthews et al.(21) demonstrated that
9

neocortical pleuritic plaques accounted for 8% of the attributable risk at
death for dementia and 11% neurofibrillary tangles(21). However although
dementia severity seems to correlate better with the tangles than the
plaques(17, 23), it has to be noted that tangles are not specific of AD (18),
these can be seen in many other pathologies.

2.1.2 Risk Factors for AD
Epidemiological studies have demonstrated that AD may be caused by
multiple factors; some from early life exposures (18, 24) and others from
risk factors present later in life (18, 25-27). Figure 2-1 shows a summary of
the risk factors known to be linked to Alzheimer‟s disease. The middle
column shows how these risk factors are associated with brain reserve(28)
and how they modify the clinical expression of dementia/AD.

2.1.2.1 Age
The main risk factor for dementia is age (6, 8, 9, 18, 21, 29, 30) and it is
also the main contributor to the attributable risk at death (18% AR)(21). The
Centers for Disease Control and Prevention (CDC) estimate that by the year
2030, one in five Americans will be over 65 years old (6). Consequently as
the population experiences demographic ageing, the prevalence of dementia
increases.
10

Figure 2-1. Risk Factors for Dementia type Alzheimer’s. Table modified from
Borenstein AR. [Unpublished Lecture Notes on Analysis and Presentation of
Results]. Class: Practical Issues in Epidemiology, Summer Semester 2010.
University of South Florida; 2010. Accessed with permission, 8/20/2010(1,
2).

The state of Florida has one of the largest elderly populations in the country.
In 2006 and 2007 Florida‟s general population was 18,089,888(31) and
18,251,243(32) respectively. Of these in 2006 there were 3,037,704(33)
adults sixty five years and over, and in 2007 there were 60,660 more seniors
over 65 than the previous year(34). In 2009 the population over 65 years of
age in Florida totaled 3,195,841(35) an increase of 158,137 seniors in 3
years. Based on the U.S. Census Bureau statistics, it is estimated that
11

Florida‟s elderly population will surpass the 7.7 million(36), or 27.1%(37) by
the year 2030.

2.1.2.2 Genetics
The Alzheimer‟s Association noted in their 2009 report that clearly familial AD
is seen in fewer than 5% of cases(10). Several studies in twins have
confirmed that heritability plays a major role at any age(26, 38). In those
over the age of 70 heritability or the proportion of disease explained by
genetic inheritance is remarkably high at 79% (38). Heritability does not
differ in gender after controlling for age(38).

One of the most studied genes involved with AD is apolipoprotein E. This
gene is involved in the transport of cholesterol in the blood. There are
several forms or alleles of the gene, allele e4 is the one that has been found
to influence the development of dementia. Recent research confirms that
although everyone who inherits one APOE-e4 gene is at high risk, those who
inherit two genes are at even higher risk(10, 13). However just like all
multifactorial conditions, carrying the gene does not guarantee that a person
will inherit AD. A recent study found that APOE-e4 has a stronger effect on
women than men but the attributable risk due to APOE-ε4 decreases with
increasing age(26).

12

When Alzheimer‟s disease occurs in people in their 40‟s and 50‟s it is refer to
as “early-onset” Alzheimer‟s disease. However, over 90% of Alzheimer‟s
disease occurs in people older than 60 years old, which is referred to as
“late-onset” AD(13). The early onset form of the disease seems to be linked
to a chromosome 14 (14q24.3), while the late onset and sporadic cases of
AD has been linked to apolipoprotein ε(APOE) on chromosome 19(17).

2.1.2.3 Gender and Hormones
Although some recent studies show no gender difference in the overall
incidence risk of developing dementia(9, 39), some say there is(10, 25).
Studies where prevalence has been measured show consistently higher rates
for women than for men, but this could be explained by longer life spans of
the former. Some studies propose that postmenopausal women taking
hormone replacement therapy have greater risk of developing dementia type
Alzheimer‟s compared to those who do not take hormone replacement
therapy(29). Women who are APOE-e4 carriers are at greater risk of
developing AD than men(26).

Much research in men and women has focused on the role of hormones,
estrogen in particular, and the timing of the onset of Alzheimer‟s disease.
Basic scientists have demonstrated the benefits of estrogen on cognition(2);
however a clear association between the use of estrogens and Alzheimer‟s
13

disease in humans has been obscured by poorly design studies(2, 17, 40)
yielding inconclusive results due to many factors such as the use of different
estrogen formulations, patterns and methods used to measure the
biomarker(40). Although controversial, most of these studies conclude that
further research is needed with younger volunteers willing to be followed for
longer periods of time.

2.1.2.4 Education & Socioeconomic Status (SES)
Epidemiological studies have shown that low education is a risk factor for AD
and that higher socioeconomic status delays the onset of the disease (10, 13,
17, 24-28). This effect may be modified and/or confounded by many other
early-life developmental factors, such as parental education, occupation,
poor nutrition, and other deprivations in childhood(24) which may lead to
lower brain volume, lower IQ and consequently lower educational
achievement(28). One of the main contributors to AR [attributable risk] at
death for dementia was small brain (12%)(21).

These observations are consistent with the “threshold” theory of brain
reserve(24, 28). Mortimer proposed that in order to see the clinical
expression of AD two conditions must be met: first, propensity to form the
pathognomonic AD lesions in the brain and second second, reaching a critical
functional brain volume in which normal cognitive function cannot be
14

sustained (28). Although (28). Although it may be possible to reverse the
accumulation of AD pathology because of its strong dependence on inherited
genes, controlling for cardiovascular comorbidities may hinder the
progression of brain loss through preservation of functional brain tissue.

2.1.2.5 Cardiovascular Risk Factors & Cognition
Well known risk factors for dementia include hypertension, hyperlipidemia,
and type 2 diabetes mellitus(28, 30, 41). The atherosclerotic process is a
common link between cardiovascular disease and dementia. Controversy
remains as to whether pharmacological treatment for cardiovascular disease,
such as statin therapy, has the ability to reduce the incidence of dementia.
Some studies have not found an association between statin use and AD(42,
43) while others have(44, 45); however many questions remain. Different
studies have studied different types of statins and this may explain some of
the differences in the findings. Statins can be lipophilic (simvastatin,
atorvastatin, cervastatin) or hydrophilic (pravastatin, fluvastatin,
rosuvastatin)(46). Different study designs, cross-sectional vs. prospective,
have been used in different populations; therefore results cannot be easily
compared. The findings suggest that cross-sectional analyses are likely to
find an inverse relationship between statin use and dementia, but that
prospective do not(47). Some prospective studies have not seen significant

15

differences in incidence(43); this may be due in part to the different study
designs, indication bias and/or confounding(48).

Haag et al. (46) studied the different types of statins in relation to AD in a
prospective study using the population-based Rotterdam Study and
surprisingly found that effect sizes were similar for both lipophilic and
hydrophilic statins; there was no dose-response relationship and a protective
effect was observed regardless of treatment duration(46).

Overall the literature is inconclusive about preventive treatment with statins
for Alzheimer‟s disease or cognitive functional improvement. More research is
needed with a standardized approach to come to any valid conclusions.

2.1.2.6 Environmental Factors & Physical Activity
Some environmental protective and risk factors for AD, occur early in life.
Borenstein et al. (2006) reviewed the early-life risk factors that may
influence the development of AD and found that Down Syndrome and trauma
to the head has been closely associated with AD in several studies; birth
weight and sibship size were inversely related to the development of AD; and
the protective effect of learning multiple languages during childhood had
inconclusive results and required further studies(24).
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Recent studies are looking closer at the effect of diet in the prevention or
delay of AD. Based on the same cardiovascular benefits, diets rich in
antioxidants, low-saturated fats, and high unsaturated fats also seem to be
protective of dementia (25, 49-51). Some studies indicate that polyphenols,
such as polyphenolic flavanoids found in grapes, apples and wine have
neuroprotective properties that slow down the beta-amyloid deposition via
oxidative stress resistance (49, 50), and reduction in toxin-build up and
chronic inflammation(52).

Other environmental factors such as smoking have been known to increase
the risk of AD (53-56). Some studies have reported benefits of smoking at
older age but this may reflect selection bias(57).

Physical activity is known to improve cardiovascular health and thus many
studies have linked it to better outcomes on patient cognition(58), risk and
progression of dementia(25, 59, 60). Depression has been linked with both
cardiovascular disease and dementia(30, 34, 41, 61, 62) as well. It is
considered a prodromal manifestation of dementia(63) and has been
associated to a two-fold increase risk for dementia(34); recent studies found
that this association is not explained by vascular risk factors(64).
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2.2 Treatment for Dementia
Unfortunately the majority of dementias are irreversible and do not respond
well to treatment. A few types of dementia are reversible, such as those
caused by hormone or vitamin imbalances, depression, and/or drugs,
including alcohol.

There are several treatments available to try to slow down the progression of
AD and control some of the symptoms. Antioxidants; cholinesterase
inhibitors such as Donepezil (Aricept®), Rivastigmine
(Excelon®),Galantamine (Razadyne®), and Cognex®; memantine
(Namenda®) which is a glutamate inhibitor; and antipsychotics or
neuroleptics that can help control behavior in later stages of AD.
Antipsychotics or neuroleptics, antidepressants and anxiolytics may be
needed to control some of the symptomatology.

2.3 Cardiovascular Epidemiology – STEMI
2.3.1 Statistics for 2009
According to the American Heart Association Heart Disease & Stroke
Statistics 2009 Update, the prevalence of cardiovascular disease (CVD) in the
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United States for 2006 was 36.3% (80.0 Million people), which is one in
every three adult Americans. Over 38 million of these, or a prevalence of
47.6%, were over the age of 60(3).

The number of myocardial infarctions in the United States in both men and
women in 2006 was 7,900,000 (9.87% of all cardiovascular diseases). Of
these, about 29% were STEMIs(3). In 2006, 55% of seniors 65 and over had
a first listed diagnosis of CHD in short stay hospitals(3). In people 40-59
years old, the prevalence of cardiovascular disease was roughly 38% and it
almost doubled for the age group 60-79 to 73%(3). Given the increase in the
prevalence and incidence of dementia and coronary heart disease with age,
their combined occurrence increases more than exponentially.

In the last several decades the mortality rate from myocardial infarctions has
decreased gradually, thanks in part to better treatment. However, the
prevalence remains at 3.6% for the year 2006(3).

Acute coronary syndromes, STEMI in particular, have been a significant
public health problem in developed nations for many years. The American
Heart Association estimates that about half a million STEMI events occur in
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the United States per year and one third of the patients with these will die
within 24 hours of the onset of ischemia(4, 5).

In the ten year span from 1996 to 2006 the number of cardiac
catheterizations decreased by 46,000 annually(3). Statistics confirm that 1.3
million PCIs, previously refered to as percutaneous transluminal coronary
angioplasty (or PTCA), were performed in the United States in 2006 alone
and approximately 50% of these were carried out in people over 65 years of
age.(3)

Although the morbidity as well as the mortality of heart disease has declined
in the last decades, the use of PCI has increased. Statistics show a 30%
increase in PCI procedures from 1996 to 2006(3) associated with a
staggering economic cost(65). In 2006 the average fee of a PCI procedure
per patient was $48,399(3). It is estimated that the direct and indirect total
cost of cardiovascular disease in the United States for 2009 reached $475.3
billion(3).

Despite global treatment improvement in cardiovascular diseases, differences
in interventions are still evident and the allocation of PCI is no different.
Minorities, women, the elderly and those with low socioeconomic conditions
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are still undertreated(4, 7, 66, 67). Some scientists argue that the overall
outcome of STEMI patients, despite known disparities, is not yet optimal(5).
This may be in part due to a lack of translation from bench to practice
amongst clinicians. To decrease this gap in knowledge and treatment, the
American College of Cardiology (ACC) and the American Heart Association
have teamed up to produce reports with the latest scientific evidence,
provide guidelines for clinicians to follow when treating STEMI patients(68)
and supply algorithms and tables to help with critical management decisions.

2.3.2 STEMI
In order to understand the treatment for STEMI, it is necessary to review the
basic pathophysiology of this condition. STEMI is a type of transmural acute
ischemia that is typically recognized early in the electrocardiogram (ECG) by
an elevation of the ST segment; the more ST segments that are elevated,
the more extensive the injury. The location of the ischemia can be
documented by the altered leads on the ECG. The diagnosis of STEMI is also
supported by the presence of ascending cardiac enzymes, specifically
troponin. The usual cause of a STEMI is a compromise in the blood flow to
the myocardium, due most frequently to a rupture of an atherosclerotic
plaque; but it can also be caused by other mechanical or dynamic
obstructions (vessel spasm) as well as inflammatory mechanisms(4).
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2.3.3 Treatment Guidelines for STEMI and PCI
Treatment for STEMI patients should be based on the recommendations
provided in the guidelines for the management of patients with ST-elevated
myocardial infarctions from the American College of Cardiology Foundation
(ACC) and the American Heart Association Task Force on Practice Guidelines
(AHA)(4, 5, 68, 69). The latest update was provided the last quarter of 2009.

2.3.4 Preventive Treatment
According to the 10-year risk based on the Framingham equation, amongst
the elderly, comorbid conditions such as established coronary heart disease,
hypertension, hypercholesterolemia, diabetes and peripheral vascular disease
increase the risk of STEMI by over 20%(4). The ACC/AHA recommends
quitting smoking and maintaining a low fat diet rich in fruits, vegetables,
whole grains and soluble fibers. Maintaining an ideal weight and an active
lifestyle is vital for preventing cardiovascular events and adverse outcomes
after the onset of the disease(3). Recommendations for the proper treatment
of hypertension are emphasized in the elderly, since many research studies
indicate that systolic hypertension is predictive of adverse outcomes in this
population, and should be treated even with normal diastolic blood
pressure(4).

22

2.3.5 Recommendations for Transportation of STEMI Patients
Modified recommendations from the ACC/AHA now encourage patients with
symptoms suggestive of STEMI to call the emergency medical services (EMS)
and seek medical treatment as soon as symptoms begin(4). Several studies
have confirmed the association between the mode of transportation to the
hospital and early reperfusion therapy(5, 68, 69). Better prognosis is
expected for those patients who arrive promptly after the onset of symptoms
to a PCI-capable facility or who are transferred within 4 hours of arriving to a
non-PCI-capable facility to a facility that can perform PCI(68). See Appendix
1.

A study by Canto JG, Zalenski RJ, Ornato JP, et al (2002) estimated that
76% of the patients choose alternative modes of transportation to the
emergency department instead of using EMS(4). Other studies indicate
longer waiting times if the patient does not arrive to the emergency
department through EMS, especially if the patient is elderly or a female(4).

The 2009 Update from the ACC/AHA for the triage and transfer for PCI newly
recommends that each community develop a system of care for STEMI
patients with specific protocols for the management and destination of those
patients who are primary PCI candidates and are not eligible for fibrinolytic
drugs and/or are in cardiogenic shock. It is advised that when patients arrive
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at non-PCI-capable centers that they receive fibrinolytic therapy as the main
source of reperfusion and be transferred, prepared with antithrombotic
medication (an anticoagulant plus an antiplatelet), as soon as possible to a
PCI-capable facility.

2.3.6 Treatment Guidelines
Treatment should be instated as soon as possible, but sometimes patient or
systemic factors delay the process. Patient factors may include refusal from
the patient(5); and although systemic factors delay the process, they do not
result in exclusion of treatment. Guidelines from 2004-2009 provide evidence
from recent clinical trials of the benefits of timing in treatment execution for
STEMI patients (4, 5, 68, 69). Studies show a higher adjusted risk of inhospital mortality in any delays to reperfusion after arrival to the hospital.
Figure 2-2 shows an algorithm for the recommended process of care for
STEMI patients.

Primary PCI is indicated as Class I if immediately available within the first 12
hours of the onset of symptoms or 90 minutes or less after arrival to a PCIcapable facility for those patients that present with Acute Coronary
Syndrome (ACS) and ST-segment elevation in the electrocardiogram in leads
V7 to V9 due to left circumflex arterial occlusion(5). Primary PCI is
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considered Class IIa for selected STEMI patients older than 75 years of age.
See appendix 2 for complete description of classifications.

Aside from primary PCI, it is important to differentiate the other types of PCI
offered. Facilitated PCI refers to access to the procedure after the
administration of pharmacological treatment such as a high-dose heparin,
platelet GP IIb/IIIa inhibitors, fibrinolytic therapy or a combination of the last
two, which act as facilitators for the PCI(69). The advantage of this method
is that it provides shorter times to reperfusion, better recovery, fewer
adverse events and better survival rates(69).

Fibrinolytic therapy works best for those patients that present early to the
hospital after the onset of symptoms; while sometimes the clinical and
graphic signs resolve with fibrinolytic therapy, most of the time this is not the
case. Thus after 90 minutes of fibrinolytic therapy and a failed reperfusion, a
rescue PCI is to be performed. Rescue PCI has been indicated given a
combination of clinical and electrocardiographic traces that indicate an infarct
artery that has not reperfused, such as a maintained ST-segment
elevated(68).
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STEMI

PCI Capable Facility

Non PCI Capable Facility

Fibrinolisis
(door to needle within 30 min)

Catheterization
(within 90 minutes)

Transfer to PCI Capable
Facility

Patient is prepared with
antithrombotics
(anticoagulant + antiplatelet)

Diagnostic
Angioplasty

3 Possible Treatments:
1. Medical/Drug therapy
2. PCI
3. CABG

Figure 2-2 Algorithm of process of care for STEMI patients as recommended
by the AHA/ACC.

The recent guideline update in 2009 modified the previous recommendation
in the triage of patients. It is now suggested that rescue PCI should be
offered to any eligible STEMI patient, regardless of age, since it offers the
greatest benefit when initiated right after the onset of ischemic
symptoms(68). Therefore elderly people that have no contraindication should
be offered the same opportunity of receiving PCI. The recommendation does
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not mention any contraindications for PCI because of mental or cognitive
status.

When faced with a less than optimal scenario, such as great distances from a
PCI-capable facility, emphasis is placed in traditional established fibrinolytic
therapy and treatments options such as “aspirin, beta-adrenoceptor-blocking
agents, vasodilator therapies, angiotensin converting enzyme (ACE)
inhibitors, and cholesterol lowering therapy(4)”.
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CHAPTER THREE
METHODS

3.1 Study Design
This is a retrospective cohort study analyzing discharge data from Florida‟s
comprehensive inpatient surveillance system for the years 2006 and 2007.
These data includes complete coverage for all 1393 zip code areas or 67
counties in the state of Florida for the reference years. Hospital discharge
data were analyzed to determine if there is a disparity in the use of cardiac
catheterization in patients 65 years of age or older with ST-Elevation
Myocardial Infarction (STEMI) with and without a diagnosis of dementia at
high volume PCI Florida hospitals.

Although PCI is the first line of treatment for patients with STEMI, individuals
receiving this treatment must first undergo cardiac catherization. To
determine where in the sequence, the possible disparity between persons
with and without dementia in usage of PCI occurs, the initial analysis was
performed based on those that undergo cardiac catheterization to determine
if indeed a PCI is the treatment of choice. Some patients that go through
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cardiac catheterization may require CABG instead. Therefore secondary
analyses were carried out to detect any possible disparities in the use of PCI
or CABG in those patients with cardiac catheterization with and without
dementia. To measure any gender disparities, a separate model was done to
separate the cohort by gender.

3.2 Study Population
Subjects for the study were identified using the International Classification of
Diseases (ICD), Ninth Revision, Clinical Modification (ICD-9-CM) codes. The
ICD Clinical Modification is the official coding system used in the United
States to code diagnoses and procedures when a patient receives services at
a hospital or clinic and is used to classify mortality as well(70). The database
under study contains ten primary codes and up to 30 secondary codes using
the referenced format.

There are over 200 hospitals in Florida(66) but not all have the same
capacity to perform Percutaneous Coronary Interventions (PCI). In order to
reduce confounding by the facility‟s volume, only hospitals that perform highvolume PCIs were considered in the statistical models. High volume PCI
hospital were identified according to the American College of Cardiology and
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the American Heart Association practice guidelines for PCI(71, 72) as those
that perform over 400 PCIs annually.

The study population consists of men and women 65 years of age and over
admitted to a high volume PCI Florida hospital during 2006 and 2007 with a
primary diagnosis of STEMI. Patients younger than 65 years of age were
excluded given that dementia is prominent in the older cohort.

3.2.1 Coding of main variables of interest using ICD-9-CM codes
Subjects for the cohort were identified using the following ICD-9-CM codes:


Acute myocardial infarction: 410.0 - 410.6, and 410.8 with a fifth digit of
0 or 1. The fifth digit describes the episode of care; in this case 0
represents episode of care unspecified and 1 represents initial episode of
care.

In order to detect any disparity of care in interventions, the following
procedural codes were used:


Catheterization codes: 37.21, 32.22, 37.23



PCI: procedure codes: 00.66, 36.01, 36.02, and 36.05.
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CABG codes: 36.10, 36.11, 36.12, 36.13, 36.14, 36.15, 36.16, 36.17,
36.18, 36.19 without additional surgeries such as valvular or aortic, and
without PCI were used.



Intervention: this variable was created to account for any PCI or CABG
procedure performed on a patient.

From the reference study population, a secondary code was extracted to
categorize those with a diagnosis of dementia. This comparison group was
identified using the following codes for dementia:


Persistent Mental Disorders: 294.0, 294.1, 294.8, 294.9



Other cerebral degenerations: 331.0-331.2, 331.7, 331.81, 331.82,
331.89, 331.9
 It is important to note that code 331.83 was excluded from the
analysis because it represents mild cognitive impairment and
these patients can be fully functional.



Memory loss and altered mental status: 780.93, 780.97



Senility without mention of dementia: 797. This code was included
because it is commonly used as a synonym for loss of mental
deterioration due to aging.
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3.2.2 Coding for all other study variables
Additional variables included in this study were as follows:


Socio-demographic factors


Gender: Male, Female (male was used as the reference category)



Age: this variable was first analyzed as a continuous variable and
then categorized as follows:





≥ 65 and < 75 years = Early Senior



≥ 75 and < 85 years = Mid Senior



≥ 85 years = Older Senior (used as reference category)

Ethnicity: American Indian or Alaska Native; Asian or Pacific
Islander; Black or African American; White; White Hispanic; Black
Hispanic; Other (if none of the ones mentioned before); or No
Response.


Based on previous study findings(12), ethnicity was
summarized for analysis under three categories: white
non-Hispanic (used as reference category); black nonHispanic/African American; and Hispanic/Other.



Zip code Socio-Economic Status (SES) measured by proxy and was
calculated as follows:
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Individual income was obtained from individual adjusted
gross income reported on the income tax returns from the
Internal Revenue Service‟s Individual Master File system for
the year 2006, which includes records for every 1040,
1040A, and 1040EZ for reporting zip code area of
residence)(73). The mean income reported for a given zip
code was used in the calculation for SES for that particular
zip code.



On July 1st, 2006 Florida‟s total population(74) was
18,089,888. According to the cumulative estimate of
population change for 2006, Florida had a 13.2% change
from 2000 to 2006(40). This percent change was used to
calculate the population change for each zip code reported in
the year 2000 for Florida. It is important to note that zip
codes with census data used in this analysis were only those
that participated in the Census 2000.



Given that per capita income is the most accurate method of
measuring income in a population, the formula used to
calculate it follows:
[Average adjusted gross income for zip code / (Population
reported for that income in 2000 + 13.2% population
growth(75))]*1000
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Tax brackets from government statistics(76) for the year 2006
were:


Tax bracket 10% = less than $7750



Tax bracket 15% = income greater or equal to $7550
and less than $30650



Tax bracket 25% = income greater or equal to $30650
and less than $74200



Tax bracket 28% = income greater or equal to $74200
or less than $154800



Tax bracket 33% = income greater or equal to
$154800 or less than $336550



Tax bracket 35% = income greater or equal to
$336550



In order to translate the above information into a categorical
zip code SES applicable to the cohort under study, the
following categories were constructed:
a) If tax bracket is in the 10% or less, it is considered zip code
SES category 1 = income less than $7,750
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b) If tax bracket is in the 15% it is considered zip code SES
category 2 = income greater or equal to $7,550 but less
than $30,650
c) If tax bracket is greater than 25% then zip code SES
category is 3 = income ≥ $30,650.


Principal Payer will be categorized as: (1) Medicare (HMO or PPO);
(2) Self Pay, Underinsured/Charity; and (3) Other (includes
Medicaid HMO; commercial Insurance (includes all types: HMO,
PPO); Worker‟s Compensation; CHAMPUS; VA; Other State or Local
Government). Category 3 was used as the reference category.



Source of Admission: categories include (1) Outside the hospital
physician Referral; (2)Transfer from a Skilled Nursing Facility; (3)ER
Physician Recommendation; (4) Court/Law Enforcement; and (5)
Information not available. Patients transferred from a hospital were
not analyzed nor those who were transfers from other facility. Given
the low number of some of these categories, the variable was recategorized into the following three:
1. Referral from physician outside the hospital
2. Recommendation from emergency room physician.
3. Other (this category included: transfer from a skilled
nursing facility; court/law enforcement; and information
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not available). This category was used as reference
category.


Admission Type: (1) Emergency; (2) Urgent; (3) Elective; or (4)
Trauma.



Hour of Arrival: used first as a continuous variable and then
categorized as follows:





00:00 - 06:00 = Early Morning



07:00 – 12:00 = Morning (used as reference)



13:00 – 17:00 = Afternoon



18:00 – 23:00 = Night



If coded „99‟

= Unknown

Weekday: this variable represents the day of the week the patient
was admitted to the hospital (Monday – Sunday).

3.2.3 Coding for comorbidity variables
Comorbidity: conditions measured at time of admission using the 30
secondary ICD-9-CM diagnosis codes in the database. Individual analysis
were performed for comorbid risk factors listed under the AHA guidelines for
Coronary Heart Disease and risk factors for Alzheimer‟s disease from the
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Alzheimer‟s Disease Association 2010 Report(3, 12) with the following ICD-9CM codes:
 Hypertension: 401.0, 401.1, 401.9, 403, 403.0, 403.01, 403.10,
403.11, 403.9, 403.90, 403.91
 Diabetes: 250.00, 250.01, 250.02, 250.03, 250.10, 250.11,
250.12, 250.13, 250.20, 250.21, 250.22, 250.23, 250.30,
250.31, 250.32, 250.33, 250.40, 250.41, 250.42, 250.43,
250.50, 250.51, 250.52, 250.53, 250.60, 250.61, 250.62,
250.63, 250.70, 250.71, 250.72, 250.73, 250.80, 250.81,
250.82, 250.83, 250.9, V58.67
 Stroke: 430, 431, 432.0, 432.1, 432.9, 433.00, 433.01, 433.10,
433.11, 433.20, 433.21, 433.30, 433.31, 433.80, 433.81,
433.90, 433.91, 434.00, 434.01, 434.10, 434.11, 434.90,
434.91, 435, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 997.02,
V12.54
 Hyperlipidemia: 272, 272.0, 272.1, 272.2, 272.3, 272.4
 Obesity: 278.00
 Cigarette smoking: 305.1
 Chronic Alcohol Abuse: 303, 303.00, 303.01, 303.02, 303.03,
303.9, 303.90, 303.91, 303.92, 303.93, V11.3, V79.1
 Depression: V79.0, 300.4, 311, 296.2, 296.20, 296.21, 296.22,
296.23, 296.24, 296.25, 296.26, 296.3, 296.30, 296.31, 296.32,
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296.33, 296.34, 296.35, 296.36, 296.5, 296.50, 296.51, 296.52,
296.53, 296.54, 296.55, 296.56
 Chronic Kidney Disease: 404, 404.0, 404.01, 404.02, 404.03,
404.9, 404.90, 404.91, 404.92, 404.93, 403, 403.00, 403.01,
403.10, 403.11, 403.9, 403.90, 403.91, 585, 585.1, 585.2,
585.3, 585.4, 585.5, 585.9
 End Stage Renal Disease: 585.6
 Congestive Heart Failure: 402.0, 402.00, 402.01, 402.1, 402.10,
402.11, 402.9, 402.90, 402.91, 404, 404.0, 404.01, 404.02,
404.03, 404.1, 404.10, 404.11, 404.12, 404.13, 404.9, 404.90,
404.91, 404.92, 404.93, 428.0, 428.1, 428.9
 Chronic Obstructive Pulmonary Disease: 490, 491, 491.0, 491.1,
491.2, 491.20, 491.21, 491.22, 492, 492.0, 492.8,
493, 493.0, 493.00, 493.01, 493.02, 493.1, 493.10, 493.11,
493.12, 493.2, 493.20, 493.21, 493.22, 493.9, 493.90, 493.91,
493.12, 494, 494.0, 494.1, 495, 495.0, 495.1, 495.2, 495.3,
495.4, 495.5, 495.6, 495.7, 495.8, 495.9, 496
Note: Heart disease is listed as a risk factor for dementia, thus the nature of
this data.
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3.2.4 Other variables of interest to be analyzed


Days to procedure (PCI and/or CABG): to properly determine the days to
procedure it was assumed that if the principal procedure or other
procedure had a PCI or CABG code greater than or equal to -3 and less
than or equal to 1, the procedure took place within 24 hours thus creating
the variables “same day PCI” or “same day CABG”.



Length of hospital stay: this variable represents the number of days from
when the patient was admitted to discharge. To analyze this variable
those patients that passed away while hospitalized were excluded from
the analysis.

3.3 RESEARCH QUESTIONS
3.3.1 Main Research Question
Is there disparity in the use of cardiac catheterization for ST-Myocardial
Infarction patients with a diagnosis of dementia versus patients without a
diagnosis of dementia after controlling for the following patient and hospital
factors: age; gender; ethnicity; zip code SES; year of hospital admission;
hour of arrival at the emergency department; source of admission; principal
payer and the following comorbidities: hypertension (HTN), diabetes mellitus
type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity, smoking history
(SMK), depression (DEP), end stage renal disease (ESRD), chronic kidney
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disease (CKD), congestive heart failure (CHF), chronic obstructive pulmonary
disease (COPD) and chronic alcohol abuse (OH)?

3.3.2 Secondary Research Questions
1. Is there is a difference in PCI use between STEMI patients with and
without dementia who underwent cardiac catheterization after controlling
for the following patient and hospital factors: age; gender; ethnicity; zip
code SES; year of hospital admission; hour of arrival at the emergency
department; source of admission; principal payer and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic abuse (OH)?

2. Is there is a disparity of CABG use between STEMI patients with and
without dementia who underwent cardiac catheterization after controlling
for the following patient and hospital factors: age; gender; ethnicity; zip
code SES; year of hospital admission; hour of arrival at the emergency
department; source of admission; principal payer and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
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(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH)?

3. Is there is a difference between the days to procedure (PCI or CABG) for
STEMI patients with and without dementia after controlling for the
following patient and hospital factors: age; gender; ethnicity; zip code
SES; year of hospital admission; hour of arrival at the emergency
department; source of admission; principal payer and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic abuse (OH)?

4. Does having dementia affects the length of hospital stay for STEMI
patients after controlling for the following patient and hospital factors:
age; gender; ethnicity; zip code SES; year of hospital admission; hour of
arrival at the emergency department; source of admission; principal
payer and the following comorbidities: hypertension (HTN), diabetes
mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP), obesity,
smoking history (SMK), depression (DEP), end stage renal disease
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(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD) and chronic abuse (OH)?

3.4 Statistical Analysis
Data analysis was performed using Statistical Analysis Software (SAS®)
version 9.1.2 software program. De-identified data were provided by year in
separate SAS files and merged to one main data set containing all necessary
information for the analysis for the years 2006 and 2007.

Before starting the study, a feasibility sample size was performed using a PS
program that works in Microsoft Windows operating system(77). Sample size
and power analysis was based on study by Sloan et al. (2004)(78).

Based on the literature review (78-80), it is expected that patients with a
diagnosis of dementia have a lower probability of receiving cardiac
catheterization. The assumption is that the failure rate is 0.15 or 15% of
non-demented STEMIs receiving PCI. The risk ratio of PCI in people with
dementia that had STEMIs is less than or equal to 0.6, “m” represents the
ratio of non-demented patients with STEMI, which are treated as the
unexposed to demented patients with STEMI, considered as the exposed.
Applying Sloan and colleagues‟ analysis, „m‟ would be 21.06, this is the ratio
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of unexposed to exposed subjects, and the relative risk of failure for exposed
subjects relative to unexposed „R‟ is 0.267.

Therefore, given that the PS program used assumes two-tailed tests, alpha
will be set at 0.1 corresponding to alpha 0.05 for a one-tailed test. Since for
this analysis the outcome can only take one of two values, received
procedure or not, an uncorrected chi-square test was performed to evaluate
the null hypothesis.
3.4.1 Sample Size and Power Analysis
This study was planned as a retrospective cohort study with 21.06
unexposed subjects per group. Prior data(78) indicate that the failure rate
among unexposed is 0.15. If the true relative risk of failure for exposed
subjects relative to unexposed is 0.267, we need to study 49 exposed
subjects and 1031.94 unexposed subjects to be able to reject the null
hypothesis that this relative risk equals 1 with probability (power) 0.8. The
Type I error probability associated with this test of this null hypothesis is 0.1.

3.4.2 Stratified Analysis
Baseline characteristics of the population were first analyzed by tabulating
the frequency of admission characteristics and comorbid conditions.
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Stratified by analyses by dementia status were carried out to identify
potential confounders among the following variables:
1.

Age: Multiple meta-analysis studies have demonstrated the link
between age and dementia(8, 30) and between age and heart
disease(3).

2.

Gender: Some studies have demonstrated that females are more likely
to suffer from dementia(29, 30) and more males than females seem to
have PCI (66).

3.

Ethnicity: Black patients are known to receive PCI less often than
whites(7, 66).

4.

Socio-economic status: there is no conclusive data on whether the
prevalence and incidence of dementia is higher in low socioeconomic
environments, the incidence of PCI has been found to be lower for
those with a disadvantaged SES class(67).

5.

Year of hospital admission: to determine if there was improvement of
care over time.

6.

Hour of arrival at the emergency department: Many studies indicate the
association of arrival time and possible PCI(68).

7.

Source of Admission: Patients who arrive at the hospital using the
emergency medical services have better survival rates(4).
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8.

Principal Payer: patients with commercial insurance seem to receive
better care than Medicare beneficiaries(81).

9.

Hospital PCI volume category: Hospitals with high volume PCI tend to
have less disparity of care in PCI(71).

10.

Comorbidities of importance in the association between dementia and
STEMI were: hypertension; hyperlipidemia; obesity; smoking status;
chronic alcohol abuse; diabetes mellitus type II; depression; stroke;
end stage renal disease; chronic kidney disease; congestive heart
failure; chronic obstructive pulmonary disease.

Patients were also stratified by gender and according to the presence of each
of the previously mentioned risk factors: hypertension, hyperlipidemia,
obesity, diabetes, stroke, cigarette smoking, alcohol abuse, depression,
chronic kidney disease (CKD), end stage renal disease (ESRD), congestive
heart failure (CHF) and chronic obstructive pulmonary disease (COPD).

Chi-square tests were used for discrete variables and t-tests for continuous
variables when comparing those with and without a diagnosis of dementia.
Age-adjusted relative risks and 95% confidence intervals were estimated
when comparing the groups using logistic regression procedures.
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Univariate models were performed to look at the distribution of continuous
risk factors for STEMI and dementia (age, length of hospital stay and SES) as
it provides the most descriptive statistics.

3.4.3 Statistical Models
3.4.3.1 Main Research Question Model
To address the main research question, multivariate logistic regression
analysis was performed to examine any differences in the use of diagnostic
cardiac catheterization for STEMI patients with and without a diagnosis of
dementia:

Model 1:
Logit=Log (px/(1-px))= α + 1dementia

where px is the probability of the xth STEMI patient receiving diagnostic
cardiac catheterization

The second model used adjusts for all potential confounders and provides
data related to the independent effects of each variable: age category,
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gender, ethnicity, zip code socio-economic status (SES), year of
hospitalization, hour of arrival, source of admission, type of payer, and the
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM),
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK),
depression (DEP), end stage renal disease (ESRD), chronic kidney disease
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).
Model 2:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of the xth STEMI patient receiving diagnostic
cardiac catheterization.

Model three was done not adjusting for zip code SES but adjusted for all
other potential confounders and provided data related to the independent
effects of each variable: age category, gender, ethnicity, year of
hospitalization, hour of arrival, source of admission, type of payer, and the
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM),
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK),
47

depression (DEP), end stage renal disease (ESRD), chronic kidney disease
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 3:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH +
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD
where px is the probability of the xth STEMI patient receiving diagnostic
cardiac catheterization.

3.4.3.2 Secondary Research Question Models
3.4.3.2.1 Secondary question #1 models
To address the first secondary question, models four to six were run to
examine any differences in the use of PCI for STEMI patients who underwent
diagnostic cardiac catheterization with and without a diagnosis of dementia.
Model 4:
Logit=Log (px/(1-px))= α + 1dementia
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where px is the probability of the xth cardiac catheterized STEMI patient
receiving PCI.

Model five was done adjusting for all potential confounders and provides data
related to the independent effects of each variable: age category, gender,
ethnicity, zip code socio-economic status (SES), year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 5:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of the xth cardiac catheterized STEMI patient
receiving PCI.
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Model six adjusted for all other potential confounders except zip code SES
and provided data related to the independent effects of each variable: age
category, gender, ethnicity, year of hospitalization, hour of arrival, source of
admission, type of payer, and the following comorbidities: hypertension
(HTN), diabetes mellitus type 2 (DM), stroke (STRK), hyperlipidemia (HLP),
obesity, smoking history (SMK), depression (DEP), end stage renal disease
(ESRD), chronic kidney disease (CKD), congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD) and chronic alcohol abuse
(OH).

Model six:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH +
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD
where px is the probability of the xth cardiac catheterized STEMI patient
receiving PCI.

3.4.3.2.2 Secondary question #2 models
To address the second secondary question, model seven was run to examine
any disparity in the use of CABG for STEMI patients who underwent
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diagnostic cardiac catheterization with and without a diagnosis of dementia
as follows:
Model 7:
Logit=Log (px/(1-px))= α + 1dementia
where px is the probability of the xth cardiac catheterized STEMI patient
receiving CABG.

Model eight was done adjusting for all potential confounders and provided
data regarding the independent effects of each variable: age category,
gender, ethnicity, socio-economic status (SES), year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 8:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
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9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of the xth cardiac catheterized STEMI patient
receiving CABG.

Model nine did not adjust for zip code SES but it did adjust for all other
potential confounders and provided data regarding the independent effects of
each variable: age category, gender, ethnicity, year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 9:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH +
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD
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where px is the probability of the xth cardiac catheterized STEMI patient
receiving CABG.

3.4.3.2.3 Secondary question #3 models
In order to determine if there was a difference between the days to
procedure for either PCI or CABG, for STEMI patients with and without
dementia, models ten to fifteen were run. The variable days to procedure
was dichotomized as performed within 24 hours or else.

Model 10:
Logit=Log (px/(1-px))= α + 1dementia
where px is the probability of xth days to PCI for cardiac catheterized STEMI
patient.

Model eleven was done adjusting for all potential confounders and provided
data regarding the independent effects of each variable: age category,
gender, ethnicity, socio-economic status (SES), year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
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(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 11:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of xth days to PCI for cardiac catheterized STEMI
patient.

Model twelve did not adjust for zip code SES but it did adjust for all other
potential confounders and provided data regarding the independent effects of
each variable: age category, gender, ethnicity, year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).
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Model 12:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH +
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD
where px is the probability of xth days to PCI for cardiac catheterized STEMI
patient.

Model thirteen is based on model ten but here the probability of days to
CABG is being measured.

Model 13:
Logit=Log (px/(1-px))= α + 1dementia
where px is the probability of xth days to CABG for cardiac catheterized STEMI
patient.

Model fourteen was done adjusting for all potential confounders and provided
data regarding the independent effects of each variable: age category,
gender, ethnicity, zip code socio-economic status (SES), year of
hospitalization, hour of arrival, source of admission, type of payer, and the
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following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM),
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK),
depression (DEP), end stage renal disease (ESRD), chronic kidney disease
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 14:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of xth days to CABG for cardiac catheterized STEMI
patient.

Model fifteen did not adjust for zip code SES but it did adjust for all other
potential confounders and provided data regarding independent effects of
each variable: age category, gender, ethnicity, year of hospitalization, hour
of arrival, source of admission, type of payer, and the following
comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM), stroke
(STRK), hyperlipidemia (HLP), obesity, smoking history (SMK), depression
(DEP), end stage renal disease (ESRD), chronic kidney disease (CKD),
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congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH).

Model 15:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5year of admission + 6hour of arrival + 7source of admission + 8payer
+ 9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH +
16DEP + 17ESRD + 18CKD + 19CHF + 20COPD
where px is the probability of xth days to CABG for cardiac catheterized STEMI
patient.

3.4.3.2.4

Secondary question #4 models

To address the last secondary question, models sixteen though eighteen
were run to identify if having dementia affects the length of hospital stay for
STEMI patients. A Cox‟ proportional hazards regression model was chosen
because it is able to explain the effect of several risk factors on time until
discharge from hospital(82). A comparison of hospitalization length of stay
between patients with dementia and patients without dementia was
performed as follows:
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Model 16:
H(t) = H0(t) x exp(1dementia)
H0(t) is the baseline hazard at time t, representing the hazard for a person
without dementia.
To explain the effect of comorbidity on time (discharge from hospital), the
following two models were executed. Model 17 adjusts for the zip code socioeconomic status proxy variable (SES) and model 18 does not adjust for the
zip code socio-economic status proxy.

Model 17:
H(t) = H0(t) x exp(1dementia +2age category + 3gender + 4ethnicity +
5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD)
H0(t) is the baseline hazard at time t, representing the hazard for a person
with the value 0 for all the predictor variables.

Model 18:
H(t) = H0(t) x exp(1dementia + 2age category + 3gender + 4ethnicity +
5year of admission + 6hour of arrival + 7source of admission + 8payer +
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9HTN + 10DM + 11STRK + 12HLP + 13obesity + 14SMK + 15OH + 16DEP
+ 17ESRD + 18CKD + 19CHF + 20COPD)

3.4.3.3 Sensitivity analysis for definition of dementia
A sensitivity analysis was conducted to determine if it is appropriate or not to
use the broad definition of dementia, as used in model 2, compared to the
strict or more specific definition of Alzheimer‟s disease. This modeling was
done to determine how dependent the definitions were. All those in the
cohort with dementia were first identified (model 2), then those with a
diagnosis of Alzheimer‟s disease (model 19), and finally a third model with
those with dementia but no Alzheimer‟s (model 20).

Model 19 was done using logistic regression to compare dementia as main
exposure and diagnostic cardiac catheterization as outcome for those
patients with a diagnosis of dementia type Alzheimer‟s. And model 20
compared non-Alzheimer‟s dementia as main exposure and diagnostic cardiac
catheterization as outcome.

Model 19:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
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9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD

where px is the probability of xth STEMI Alzheimer‟s disease dementia patient
receiving diagnostic cardiac catheterization.

Model 20:
Log [px/(1-px)]=0 + 1dementia + 2age category + 3gender + 4ethnicity
+ 5SES + 6year of admission + 7hour of arrival + 8source of admission +
9payer + 10HTN + 11DM + 12STRK + 13HLP + 14obesity + 15SMK +
16OH + 17DEP + 18ESRD + 19CKD + 20CHF + 21COPD
where px is the probability of xth STEMI non-Alzheimer‟s demented patient
receiving diagnostic cardiac catheterization.
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CHAPTER 4
RESULTS

4.0

Descriptive Statistics

4.1

Characteristics of the Cohort

The Florida hospital inpatient surveillance system database for the years
2006 and 2007 contained data for 13,148 STEMI patients over 65 years of
age for the years 2006 and 2007. After restricting the cohort to only those
seen at high volume PCI facilities, 8,331 STEMI patients were eligible for
analysis. Table 4-1 describes the characteristics of the cohort in detail.

There were 7.3% (n=605) of patients with a diagnosis of dementia and of
these, 32.7% (n=198) were diagnosed with Alzheimer‟s disease. Most
patients were early senior white males (n=2060).The majority of patients,
85.4% (n=7112) were admitted through the emergency department and
79.4% (n=6615) were coded as emergencies. There were no differences in
distribution by time or day of the week admitted to the hospital.
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Table 4-1 Baseline Characteristics of Elderly STEMI Patients in Florida during
2006-2007.
Total cohort
%(N=8,331)
Age Category
65-74
75-84
85+

Patients without
Dementia
%(N=7726)

Patients with
Dementia
%(N=605)

P Value
for
difference

45.71% (3808)
37.03% (3085)
17.26% (1438)

48.40% (3739)
36.76% (2840)
14.85% (1147)

11.40% ( 69)
40.50%( 245)
48.10% ( 291)

P<0.0001

Gender
Men
Women

56.73% (4726)
43.27% (3605)

58.02% (4483)
41.98% (3243)

40.17% ( 243)
59.83% ( 362)

P<0.0001

Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic & Others

83.38% (6946)
4.65% ( 387)
11.98% ( 998)

83.57% (6457)
4.44% ( 343)
11.99% ( 926)

80.83% ( 489)
7.27% ( 44)
11.90% ( 72 )

P=0.0061

Payer
Medicare
Self Pay/Charity
Other

89.86% (7486)
1.03% ( 86)
9.11% ( 759)

89.50% (6915)
1.09% ( 84)
9.41% ( 727)

94.38% ( 571)
0.33% (
2)
5.29% ( 32)

P=0.0005

Received Diagnostic
Cardiac Catheterization

77.24% (6435)

79.63% (6152)

46.78% ( 283)

P<0.0001

Received PCI

67.16% (5595)

69.29% (5353)

40.00% ( 242)

P<0.0001

9.33% ( 777)

9.77% ( 755)

5.99 ( 5.90)

5.98 ( 5.93)

Received CABG
Length of Hospital Stay*
Risk Factors
Hypertension
Diabetes Mellitus
Stroke
Hyperlipidemia
Obesity
Smoking
Alcohol abuse
Depression
Chronic Kidney Disease
End Stage Renal Disease
Congestive Heart Failure
Chronic Obstructive
Pulmonary Disease

67.72% (5642)
29.08% (2423)
4.89% ( 407)
56.28% (4689)
6.51% ( 542)
12.86% (1071)
0.54% ( 45)
5.40% ( 450)
14.38% (1198)
1.42% ( 118)
29.77% (2480)
21.21% (1767)

*Continuous data are mean (SD)
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67.87% (5244)
29.21% (2257)
4.71% ( 364)
57.33% (4429)
6.76% ( 522)
13.47% (1041)
0.54% ( 42)
4.72% ( 365)
13.85% (1070)
1.40% ( 108)
28.86% (2230)
21.14% (1633)

3.64% (

22)

P<0.0001

6.09 ( 5.55)

P=0.0384

65.79% (
27.44% (
7.11% (
42.98% (
3.31% (
4.96% (
0.50% (
14.05% (
21.16% (
1.65% (
41.32% (
22.15% (

398)
166)
43)
260)
20)
30)
3)
85)
128)
10)
250)
134)

P=0.2898
P=0.3546
P=0.0085
P<0.0001
P=0.0009
P<0.0001
P=0.8774
P<0.0001
P<0.0001
P=0.6092
P<0.0001
P=0.5575

4.1.1 Age
The average age of the sample was 76.30 years (SD 7.85; 95% CI SD 7.73 7.97) (Table 4-1). Figure 4-1shows the age distribution of cohort. For
practical comparisons, the cohort was categorized into three age groups
commonly used in the literature: early seniors (65-74 years old), mid-seniors
(75-84 years) and seniors over 85 years of age. Most of the sample were in
the early senior category 45.7% (n=3808) and the least number of subjects
were over the age of 85, 17.3% (n=1438).

Males comprised most of the early seniors 66.8% (n=2544) while females
the older senior group 61.5% (n=885). There was a crossover effect at 78
years of age (Figure 4-2); 48.4% (n=3739) of non-demented patients were
in the early senior category while 48.1% (n=291) of those with dementia
were in the oldest old category, over 85 years of age.
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Percent of STEMI Patients

Age distribution of Elderly STEMI Patients in
Florida during 2006-2007
6%
5%
4%
3%
2%
1%
0%

Age of STEMI Patients
Percent of STEMI Patients

Figure 4-1 Age distribution of Elderly STEMI patients in Florida during 20062007.

Percent of STEMI Patients

Age distribution of Elderly STEMI Patients in Florida
during 2006-2007 by Dementia Status
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Figure 4-2 Age distribution of Elderly STEMI patients in Florida during 20062007 by Dementia Status. Percent of STEMI patients is shown for each
diagnostic category
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4.1.2 Ethnicity

The majority of the cohort were white non-Hispanic 83.4% (n=6946) (Table
4-2) followed by 12.0% (n=998) Hispanics/Other. Most of the non-Hispanic
whites and Hispanics/Other were males 56.4% (n=3917) and 61.82%
(n=617) respectively. Blacks accounted for the minority of the cohort but
were more evenly distributed by gender; black females accounted for 50.4%
(n=195) of that sample. However in the Hispanic/other category there were
24% fewer females than males.

Table 4-2 Ethnic Characteristics of Elderly STEMI Patients in Florida during
2006-2007.

Ethnicity
White NonHispanic
83.4%(6946)
Black NonHispanic
4.6%(387)
Hispanic/
Others
12.0%(998)

Males
%(n=4726)

Females
%(n=3605)

Early Senior
%(n=3808)

Mid Senior
%(N=3085)

Older Senior
%(N=1438)

82.9%(3917)

84.0%(3029)

80.7%(3074)

84.7%(2614)

87.5%(1258)

4.1%(192)

5.4%(195)

5.7%(217)

4.0%(125)

3.1%(45)

13.1%(617)

10.6%(381)

13.6%(517)

11.2%(346)

9.4%(135)

Black non-Hispanics received the least number of interventions and had the
lowest prevalence of depression, but had the highest prevalence of dementia,
Alzheimer‟s, obesity, hypertension, diabetes, chronic kidney disease, end
stage renal disease, congestive heart failure and current or history of
smoking than any other ethnic category(Figure 4-3).
65

4.1.3 Comorbidity of the Cohort
Over two thirds of the cohort was hypertensive (67.7% n=5642); demented
patients were slightly less hypertensive 65.8% (n=398). When stratified by
ethnicity Black/African American non-Hispanics had the highest prevalence of
hypertension (80.1% n=310). Refer to Figure 4-3 for specific comorbidities
of the cohort by ethnicity.

There were 2423 coded diabetics in the cohort (29.1%), of these 29.2%
(n=2257) were non-demented patients and 27.4% (n=166) were demented
patients. Forty five percent of Black/African American non-Hispanics were
diabetic (n=173) and 26.4% (n=102) had chronic kidney disease (CKD).
Overall there were 14.4% (n=1198) of patients in the cohort with a diagnosis
of CKD; demented patients had the highest prevalence of CKD, 21.2%
(n=128). Only 1.4% (n=118) of patients in the cohort had end stage renal
disease (ESRD), however demented patients had the highest prevalence
(1.6% n=10) and when stratified by ethnicity, Blacks had the highest
prevalence (5.7% n=22).

Over half of the cohort was hyperlipidemic (56.3% n=4689) yet only 6.5%
(n=542) of the cohort was obese. Non-demented patients had the highest
prevalence of hyperlipidemia, 57.3% (n=4429). White non-Hispanics had the
highest number of hyperlipidemics, 57.4% (n=3986).
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Twenty one percent of the cohort (n=1767) were coded as having chronic
obstructive pulmonary disease (COPD) and 21.6% (n=1500) of whites
carried the diagnosis. Almost 13% (n=1071) of the cohort had a history of
smoking or were current smokers, of these non-demented patients smoked
the most 13.5% (n=1041). When stratified by ethnicity, Black/African
American non-Hispanics smoke or smoked the most, 13.7% (n=53). Very
few people in the cohort were chronic alcoholics, 0.5% (n=45).

Only 4.9% (n=407) of the patients in the cohort had a history of a stroke or
had a current stroke; however 7.1% (n=43) of demented patients and 5%
(n=350) of White non-Hispanics had the highest prevalence. There were
5.4% (n=450) patients in the cohort with a diagnosis of depression; 14% of
demented patients were depressed compared to 4.7% of non-demented
patients and Hispanics/Other had the highest prevalence of depression from
all other ethnic groups, 6.2% (n=62).
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Prevalence of comorbidities among STEMI patients by
ethnicity
HTN*
HLP*
CHF*
DM*
Hispanic/Other

COPD*

N=998

CKD*

Black non-Hispanic
Current Smoking

N=387

Obesity

White non-Hispanic

Depression

N=6946

Stroke
ESRD*
Current Alcohol Use

0%

20%

40%

60%

80%

100%

% STEMI Patients
*ESRD (End Stage Renal Disease), CKD (Chronic Kidney Disease), COPD (Chronic Obstructive Pulmonary
Disease), CHF (Congestive Heart Failure), DM (Diabetes Mellitus), HLP (Hyperlipidemia), HTN
(Hypertension).

Figure 4-3 Prevalence of Comorbidities among STEMI patients by ethnicity.
4.1.4 Source and Days of Admissions
The source of most admissions was through emergency room 85.4%
(n=7112) and as referrals 13.9% (n=1155). There were no significant
differences for source of admission by gender, age category, ethnicity, or day
of admission. Demented patients were more likely to be admitted on Friday
17.2% (n=104) but this was not significant when compared to nondemented patients (Table 4-3).
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Table 4-3 Day of Week of Hospital Admission for STEMI Patients with and
without dementia in Florida during 2006-2007.
Total cohort
%(N=8,331)

Patients without
Dementia
%(N=7726)

Patients with
Dementia
%(N=605)

P Value
for
difference

Monday

15.1% (1257)

15.0% (1162)

15.7% (95)

P=0.7344

Tuesday

14.1% (1176)

14.1% (1090)

14.2% (86)

Wednesday

15.0% (1249)

15.1% (1167)

13.5% (82)

Thursday

13.8% (1151)

13.8% (1069)

13.5% (82)

Friday

15.0% (1252)

14.9% (1148)

17.2% (104)

Saturday

13.3% (1109)

13.4% (1034)

12.4% (75)

Sunday

13.6% (1137)

13.7% (1056)

13.4% (81)

Day of
Admission

4.1.5 Type of Admissions and Payer
Most type of admissions were emergencies 79.4% (n=6615). There were no
major differences in type of admission by payer, gender or dementia status.
Payment distribution was allocated into three categories: Medicare payers,
self-pay or charity, and other means including commercial insurance. Nearly
everyone paid through Medicare 89.9% (n=7486); 9.1% (n=759) paid
through other means and only 1.0% (n=86) were self-pay.
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4.1.6 Length of Hospital Stay
The mean length of the hospital stay for survivors in the cohort was 6.2 days
(SD 5.9; 95% CI 6.05-6.35; p<0.0001). Table 4-4 shows detail data for this
variable by dementia status. Females had slightly longer hospital stays than
males (6.32 days vs. 6.07 days). Most females (40.0% n=1261) stayed 4-7
days in the hospital while the majority of males (39.1% n=1667) stayed for
2-3 days p<0.0001.

Table 4-4 Length of Hospital Stay for survivor STEMI Patients with and
without dementia in Florida during 2006-2007.

Total
survivors
%(N=7422)

Patients
without
Dementia
%(N=6921)

Patients with
Dementia
%(N=501)

2.9%(216)

2.9%(201)

3.0%(15)

Within 2-3 days

36.0%(2671)

36.8%(2547)

24.7%(124)

Within 4-7 days

36.5%(2708)

36.0%(2490)

43.5%(218)

Within 8- 14 days

17.6%(1309)

17.4%(1203)

21.2%(106)

Within 15-30 days

5.8%(433)

5.8%(401)

6.4%(32)

Greater than 1 month

1.15%(85)

1.1%(79)

1.2%(6)

Length

Less or equal 1 day
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P Value
for
difference
<0.0001

4.2

Outcomes for Cardiovascular Interventions

% of STEMI Patients Who
Received Intervention

Percent of STEMI Patients Who Received Specific
Interventions
90%
80%

77%

67%

70%
60%
50%
40%
30%
20%

9%

10%
0%
Diagnostic
Catheterization
N=6435

PCI

N=5595

CABG

N=777

Intervention

Figure 4-4 Percent of STEMI patients who received interventions in Florida
during 2006-2007.
Over three quarters of STEMI patients in the cohort received diagnostic
cardiac catheterization, 77.2% (n=6435); slightly more than two thirds,
67.2% (n=5595) underwent PCI and 9.3% (n=777) received CABG (Figure
4-4). When looking only at those who received catheterizations, 73.8%
(n=6150 p=<0.0001) received some form of intervention, either PCI or
CABG. Sixty percent of the cohort (n=4986) received PCI on the same day of
admission and 5.4% (n=449) received CABG. In general, those in the older
group, patients with dementia, and females were less likely to receive any
kind of intervention. Figures 4-4 to 4-11 show the distribution of
interventions by different variables of interest.
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Percent of STEMI Patients Who Received Specific
Interventions by Dementia Status

% of STEMI Patients Who
Received Intervention

90%
80%

80%

69%

70%
60%
50%

47%

40%

40%

Demented

30%
20%

4%

10%

NonDemented

10%

0%
Diagnostic
Catheterization
N=6435

PCI
N=5595

CABG
N=777

Intervention

Figure 4-5 Percent of STEMI patients who received interventions by
dementia status.

% of STEMI Patients Who
Received Intervention

Percent of STEMI Patients Who Received Specific
Interventions by Gender
90%
80%
70%

82%
71%

70%

63%

60%
50%
40%
30%
20%

12%

10%

6%

0%
Diagnostic
Catheterization

(N=6435)

PCI

(N=5595)
Intervention

CABG

(N=777)

Males
Females

Figure 4-6 Percent of STEMI patients who received interventions by gender.
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% of STEMI Patients Who Received Intervention

Percent of STEMI patients who received intervention by
age category
100%
90%
80%

87%
78%

76%
67%

70%
60%
50%

50%

45%

40%
30%
20%

12% 10%

10%

2%

0%
Diagnostic
Catheterization
(N=6435)
65-74

PCI

(N=5595)

CABG
(N=777)

Age Category
75-84

85+

Figure 4-7 Percent of STEMI patients who received interventions by age
category.
Overall the very old, those over the age of 85, received 30% fewer
interventions (diagnostic cardiac catheterization or PCI) than the early
seniors (Figure 4-7). When stratifying the age categories by dementia status
the percent of STEMI patients who received catheterization or PCI was the
same.
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% of STEMI Patients Who Received
diagnostic catheterization

Percent of STEMI patients who received diagnsotic cardiac
catheterization by age category and dementia status
100%

87%

90%

80%

80%
70%

61%

61%

55%

60%

50%
40%

32%

30%
20%
10%
0%
65-74

75-84

(N=3085)

(N=3808)

85+

(N=1438)

Age Category
Dementia
No-Dementia

Figure 4-8 Percent of STEMI patients who received diagnostic cardiac
catheterization by age category and dementia status.

% of STEMI Patients Who Received PCI

Percent of STEMI patients who received PCI by age
category and dementia status

76%

80%

68%

70%
60%

52%

50%

50%

50%

40%

29%

30%
20%
10%
0%
65-74

(N=3808)

75-84

(N=3085)

Age Category
Dementia
No-Dementia

85+

(N=1438)

Figure 4-9 Percent of STEMI patients who received PCI by age category and
dementia status.
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% of STEMI Patients Who
Received CABG

Percent of STEMI patients who received CABG by age
category and dementia status
14%

12%

12%

10%

10%
8%

7%

6%

6%
4%

3%

2%

1%

0%

65-74

(N=3808)

75-84

85+
(N=1438)

(N=3085)

Age Category
Dementia

No-Dementia

Figure 4-10 Percent of STEMI patients who received CABG by age category
and dementia.

% of STEMI Patients Who Received
Intervention

90%
80%

Percent of STEMI patients who received intervention
by SES category
78% 76% 77%
69%

70%

65% 67%

60%
50%

40%
30%
20%

7%

10%

10% 10%

0%
Diagnostic
Catheterization
(N=5985)
SES* < $7,790

PCI

(N=5215)

CABG

(N=702)

Age Category
SES* ≥ $7,790 < $30,650

SES* ≥ $30,650

Figure 4-11 Percent of STEMI patients who received interventions by SES
category.
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4.3

Comorbidities and Use of Interventions

% of STEMI Patients with comorbidity

80%

Prevalence of Comorbidity among STEMI patients by Age
Category

70%
60%
50%
40%

65-74

30%

75-84

20%

85+

10%
0%

Comorbidity
*Alcohol (Current Alcohol abuse), ESRD (End Stage Renal Disease), DEP (Depression), CKD (Chronic
Kidney Disease), Smoking (Current Smoking), COPD (Chronic Obstructive Pulmonary Disease), CHF
(Congestive Heart Failure), DM (Diabetes Mellitus), HLP (Hyperlipidemia), HTN (Hypertension).

Figure 4-12 Prevalence of Comorbidities for STEMI patients in Florida by age
category.
4.3.1 Hypertension
More than two thirds of the cohort was hypertensive 67.7% (n=5642). Table
4-5 provides a detail description of the hypertensive patients. Seven percent
of the individuals with high blood pressure had dementia and 2.2% had a
diagnosis of Alzheimer‟s disease. Of the total number of hypertensive
subjects, only 5.4% had a stroke, 6% were depressed, 7.7% were obese,
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12% currently smoked or had a history of smoking, 33.5% were diabetic and
62% were hyperlipidemic.

Table 4-5 Characteristics of hypertensive STEMI patients in Florida during
2006-2007.
Patients with
Hypertension
% (n=5642)

Patients without
Hypertension
% (n=2689)

Chi-square
Probability

Gender
Men
Women

54.50% (3075)
45.50% (2567)

61.40% (1651)
38.60% (1038)

p<0.0001

Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic & Others

82.17% (4636)
5.49% ( 310)
12.34% ( 696)

85.91% (2310)
2.86% ( 77)
11.23% ( 302)

p<0.0001

76.85% (4336)

78.06% (2099)

p=0.2194

66.55% (3755)

68.43% (1840)

p=0.0889

9.38% ( 529)

9.22% ( 248)

p=0.8220

7.05% ( 398)
2.23% ( 126)
33.55% (1893)
5.41% ( 305)
61.93% (3494)
7.71% ( 435)
12.00% ( 677)
0.41% ( 23)
5.99% ( 338)
17.81% (1005)
1.84% ( 104)

7.70% ( 207)
2.68% ( 72)
19.71% ( 530)
3.79% ( 102)
44.44% (1195)
3.98% ( 107)
14.65% ( 394)
0.82% ( 22)
4.17% ( 112)
7.18% ( 193)
0.52 ( 14)

p=0.2898
p=0.2132
P<0.0001
P=0.0014
P<0.0001
P<0.0001
P=0.0007
P=0.0169
P=0.0006
P<0.0001
P<0.0001

9.23% (1649)

30.90% ( 831)

P=0.1177

21.64% (1221)

20.30% ( 546)

P=0.1630

Received Cardiac
Catheterization
Received PCI
Received CABG
Other Medical
Conditions
Dementia
Alzheimer’s
Diabetes Mellitus
Stroke
Hyperlipidemia
Obesity
Smoking
Alcohol abuse
Depression
Chronic Kidney Disease
End Stage Renal
Disease
Congestive Heart
Failure
COPD

4.3.2 Hyperlipidemia
Over half of the cohort was hyperlipidemic 56.3% (n=4689). Most were early
and mid seniors (51.78% and 35.2% respectively) and 57.9% were males
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(see figure 4-12). Of all the patients with high lipids, a total of 82% received
cardiac catheterization (OR 1.85, 95% CI 1.67-2.06) and 71.8% received PCI
(OR 1.61, 95% CI 1.47-1.77). There was no significant difference in
receiving CABG for those with and without hyperlipidemia. Only 5.5% (OR
0.56, 95% CI 0.47-0.66) of the hyperlipidemics had dementia and 1.7% (OR
0.52, 95% CI 0.39-0.69) had a diagnosis of Alzheimer‟s disease.

Patients with hyperlipidemia were 1.5 times more likely to have diabetes
(95% CI 1.33-1.61), two times as likely (OR 2.03, 95% CI 1.85-2.23) to
have hypertension, 1.9 times more likely to be obese (95% CI 1.58-2.31)
than non-hyperlipidemics and smoked 20% more than patients without high
lipids. However depression was not significant for these patients (OR 1.04,
95% CI 0.86-1.27) and they were less likely to have chronic kidney disease
(OR 0.86 95% CI 0.76-0.97), end stage renal disease (OR 0.44, 95% CI
0.30-0.64), congestive heart failure (OR 0.73, 95% CI 0.66-0.80) and less
COPD (OR 0.81, 95% CI 0.73-0.90).

4.3.3 Diabetes Type 2
Over a quarter of the cohort was diabetic, 29.1% (n=2423) and of these
76.1% received cardiac catheterization; however diabetics were 0.78 times
less likely to receive PCI than non-diabetics (95% CI 0.70-0.86) but 1.4
times more likely to go through CABG (95% CI 1.19-1.62). Gender was not
a significant factor for diabetes. Early seniors were 36% more diabetic than
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older seniors (49% vs. 13%). More Black non-Hispanic/African American
44.7% (n=173) were diabetics than any of the other ethnic groups.
Dementia was not a significant factor for having diabetes (OR 0.92, 95% CI
0.76-1.10).

Two thirds of the diabetics had high lipids (OR 1.46 95% CI 1.33-1.61); they
were 2.1 times more likely to have hypertension (95% CI 1.84-2.30); 2.4
times more likely to be obese (95% CI 2.03-2.88) and much more likely to
have end stage renal disease (OR 2.84, 95% CI 1.97-4.09) and chronic
kidney disease (OR 2.07, 95% CI 1.83-2.35). Diabetics were also 1.5 times
more likely than non-diabetics to have congestive heart failure. Nonetheless,
they were less likely to smoke than non-diabetics (OR 0.80, 95% CI 0.590.93).

4.3.4 Stroke
Roughly 5% of the cohort (n=407) had had either current stroke or history of
stroke. Females had 2% more history or current strokes than males 50.9%
versus 49.1% respectively (OR 0.72, 95% CI 0.59-0.88) and mid-seniors had
more history or current strokes than seniors over 85 years of age, 41.77%
vs. 19.90% (p<0.009). Ethnicity was not a statistically significant factor for
patients with or without a current stroke or medical history of one
(p=0.3004).
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Patients with a history of or current stroke were 0.5 times less likely to have
cardiac catheterizations than those without strokes (95% CI 0.42-0.63) and
0.4 times less likely to receive PCI (95% CI 0.37-0.55); however, they were
more likely to receive CABG than those without a current stroke or history of
one (OR 1.45, 95% CI 1.08-1.96). Patients with dementia had had 2.4%
more history or current strokes than non-demented patients, 7.11% vs.
4.71% (OR 1.55, 95% CI 1.11-2.15).

Seventy five percent of patients with a history of or current stroke had
hypertension (OR 1.45, 95% CI 1.15-1.82) and were more likely to be
depressed (OR 1.48, 95% CI 1.01-2.16) although this was not statistically
significant; these patients were more likely to have COPD (OR 1.59, 95% CI
1.28-1.98), chronic kidney disease (OR 1.80, 95% CI 1.41-2.29), and
congestive heart failure (OR 1.98, 95% CI 1.62-2.42) than those without a
current stroke or history of one.

4.3.5 Smoking and Alcohol abuse
Roughly one eighth (12.9% n=1071) of the sample currently smoked or had
smoked. Most smokers were in the early senior category (70.6% n=756)
and were males (62.4% n=668). Blacks/African Americans non-Hispanics
were the ethnic group that smoked the most (13.7%). Eighty eight percent
of smokers were catheterized, 77.6% received PCI, and 11.5% went through
CABG (Figure 4-13). Non-demented patients smoked much more than those
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with dementia (13.5% vs 4.96%) and only 3.0% of the patients diagnosed
with Alzheimer‟s disease were smokers. Almost two thirds of smokers were
hypertensive (63.21% n=677) and 60% (n=644) had hyperlipidemia (OR
1.20, 95% CI 1.05-1.37). Smokers were 5.5 times more likely than nonsmokers to use alcohol (95% CI 3.05-9.95) and 3.6 times more likely to
have COPD than non-smokers (95% CI 3.11-4.07).

Percent of smoker and non-smoker
patients who received intervention

Percent of smoker and non-smoker STEMI patients who
received interventions
100%
90%
80%

88%
76%

78%
66%

70%
60%
50%

40%
30%
20%

11%

10%

9%

0%

Diagnostic
Catheterization

PCI
SMOKERS N=1071

CABG
NON-SMOKERS N=7260

Figure 4-13 Percent of smoker and non-smoker STEMI patients in Florida
during 2006-2007 who received interventions.
Alcohol abusers were 0.5 times less likely to be hypertensive than nonalcohol drinkers (95% CI 0.28-0.89) and were more likely to be early seniors
(68.9% n=31). All other associations with alcohol abuse were not statistically
significant.
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4.3.6 Congestive Heart Failure
Almost 30% (n=2480) of the cohort had congestive heart failure; most of
these were in the mid-senior category (41.3% n=1025). Compared to
patients without CHF, these patients were less likely to receive diagnostic
cardiac catheterization (OR 0.46, 95% CI 0.41-0.51) or receive PCI (OR 0.38
95% CI 0.34-0.42), but were more likely to have CABG (OR 1.58, 95% CI
1.35-1.84). Ten percent of those with CHF had dementia (OR 1.73, 95% CI
1.46-2.05) and were 1.5 times more likely to have Alzheimer‟s (95% CI
1.11-1.98). Over 7% of CHF patients had strokes or had history of a stroke
(OR 1.98, 95% CI 1.62-2.42) and more than a third were diabetic (35.5%
n=2480) (OR 1.54, 95% CI 1.4-1.7).

CHF patients were 0.7 times less likely to be hyperlipidemic (95% CI 0.660.80) or smokers (95% CI 0.60-0.81) than non-CHF patients, but were 1.5
times more likely to be depressed (95% CI 1.27-1.87). Almost a third of CHF
patients suffered from COPD, 31.8% (OR 2.32, 95% CI 2.08-2.59); they
were 2.9 times more likely to have early stage renal disease (95% CI 2.044.24) and 3.3 times more likely to have chronic kidney disease (95% CI 2.93.7) than non-CHF patients.

4.3.7 End Stage Renal Disease and Chronic Kidney Disease
Only 1.4% (n=118) of the total cohort and 1.6% (n=10) of those with
dementia had a diagnosis of end stage renal disease (ESRD), but of those
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diagnosed with ESRD, 8.5% had dementia (Figure 4-14) and 2.5% were
diagnosed with Alzheimer‟s. Patients with ESRD were less likely to receive
diagnostic cardiac catheterization (OR 0.49, 95%CI 0.34, 0.71) or PCI (OR
0.59, 95% CI 0.41, 0.86) than those without it and 6% of the patients with
ESRD received CABG (OR 0.6096, 95% CI 0.28, 1.31).

Most of the ESRD patients were in the early senior group (49.1%) and were
white non-Hispanic (69.49%). ESRD patients were 3.6 times more likely to
have hypertension (95% CI 2.05, 6.28), 2.8 times more likely to have
diabetes (95% CI 1.97, 4.09) and 2.9 times more likely to have CHF (95% CI
2.04, 4.24) than patients without ESRD; however they were 0.4 times less
likely to have hyperlipidemia (95% CI 0.30, 0.64).

Prevalence of dementia among STEMI patients
with ESRD* and CKD*
% of STEMI patients

100%

92%

89%

90%
80%
70%
60%
50%

Dementia

40%

No-Dementia

30%
20%
10%

8%

11%

0%

ESRD*

CKD*

*ESRD (End Stage Renal Disease), CKD (Chronic Kidney Disease).

Figure 4-14 Prevalence of dementia among STEMI patients with ESRD* and
CKD* who received interventions.
83

Fourteen percent (n=1198) of the cohort had CKD. Patients with CKD were
less likely to receive diagnostic cardiac catheterization (OR 0.44 95% CI
0.38, 0.50) and PCI (OR 0.45, 95% CI 0.40, 0.51) but were 1.3 times more
likely to go through CABG (95% CI 1.04, 1.55) than those without CKD. Most
were males (61.5%), mid-seniors (40.6%) and White-non Hispanic (79%).
Those diagnosed with CKD were 1.7 times more likely to have a diagnosis of
dementia (95% CI 1.36, 2.05) and 1.9 times more Alzheimer‟s (95% CI
1.35, 2.63) than those without CKD (Figure 4-14).

Patients with CKD were 1.8 times more likely to have had strokes or a
current stroke (95% CI 1.41, 2.29), more likely to be hypertensive (OR 2.8,
95% CI 2.38, 3.29), diabetic (OR 2.07 95%CI 1.83, 2.35), 1.5 times more
likely to have COPD (95% CI 1.28, 1.70) and 3.3 times more likely to have
CHF (95% CI 2.91, 3.74) than patients without CKD. Those with CKD were
0.9 times less likely to have hyperlipidemia (95% CI 0.76, 0.97) and 0.5
times less likely to be smokers (95% CI 0.44, 0.68).

Patients with CKD were 16.6% more hyperlipidemic (53.0% vs.36.4%) and
smoked 2% more than patients with ESRD (7.93% vs. 5.93%); however
there were 10.3% more patients with ESRD that were diabetics than were
there CKD patients with diabetes (53.4% vs. 43.1%). There were 2.1% more
patients with ESRD that were obese than there were obese CKD patients
(Figure 4-15).
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% of STEMI patients with risk factor
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Prevalence of common risk factors among STEMI
Patients with end stage renal disease (ESRD) and
chronic kidney disease (CKD)
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* COPD (Chronic Obstructive Pulmonary Disease), DM (Diabetes), CHF (Congestive Heart Failure), HLP
(Hyperlipidemia), HTN (Hypertension).

Figure 4-15 Prevalence of common risk factors among STEMI patients with
end stage renal disease (ESRD) or chronic kidney disease (CKD) in Florida
during 2006-2007.
4.3.8 Depression
There were 450 patients diagnosed with depression in the cohort (5.40%)
and most were women (64% n=288). Older seniors were less depressed
than the younger seniors (21.6% vs. 38.7%) and Black/African American
non-Hispanics were the least depressed (2.7%). Two thirds of those
diagnosed depressed received cardiac catheterization (OR 0.56, 95% CI
0.45-0.68) and 54.4% received PCI (OR 0.56, 95% CI 0.47-0.68). Nineteen
percent of depressed patients were demented (OR 3.30, 95% CI 2.56-4.24)
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and those depressed were 3.3 times more likely to have Alzheimer‟s disease
than non-depressed patients (95% CI 2.20-4.89).

Three quarters of all depressed patients were hypertensive (OR 1.47, 95% CI
1.18-1.82), 33.3% had COPD (OR 1.9, 95% CI 1.58, 2.37) and depressed
patients were 1.5 times more likely to have CHF than non depressed (95% CI
1.26, 1.87). Although most had hyperlipidemia (57.3%), it was not
statistically significant. A diagnosis of depression was 1.5 times more likely to
be associated with CHF (95% CI 1.26-1.87) than non-depressed.

4.3.9 Obesity
Only 6.5% (n=542) of the cohort was coded obese. Of these, 12% smoked,
16% had CKD, 23% COPD and 28% CHF, but the associations were not
statistically significant. However over 70% of the obese had hyperlipidemia
(OR 1.9, 95% CI 1.58-2.31) and were 2.4 times more likely to be diabetic
than non obese patients (95% CI 2.03-2.88). Over 80% of the obese were
hypertensive (OR 2.02, 95% CI 1.62-2.50).

4.4 Overview of Descriptive Statistics by Dementia
The prevalence of dementia in the study was 7.3%. Most demented patients
were White non-Hispanic but Black/African American non-Hispanics had the
highest prevalence of dementia among all ethnic groups (11.4%). Almost
60% of all demented were females. As expected, most demented patients
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belonged to the 85 or older age category (48.1%). One third of demented
patients had a diagnosis of AD.

The highest percentage of demented patients arrived to the hospital in the
afternoon hours (25.8%) while most non-demented patients arrived to the
hospital in the morning (25.6%). Ninety four percent of demented patients
paid through Medicare.

Only 46.8% of demented patients received diagnostic cardiac catheterization,
40% received PCI and 3.6% received CABG (refer to figure 4-5). Only
37.5% of demented patients received PCI within the first 24 hours after
arrival to the hospital compared to 61.7% of non-demented who did receive
PCI within a day; 2.6% of demented patients received CABG within the first
24 hours while 5.6% of non-demented patients received it on the same day
of arrival.

When comorbidities were stratified by dementia status, demented patients
were 1.55 times more likely to have or have had a stroke than non-dements
(95% CI 1.11-2.15); over three times more likely to have depression (OR
3.25, 95% CI 2.52-4.19); 1.67 times more likely to have chronic kidney
disease (95% CI 1.36-2.05) and 1.7 times more likely to have congestive
heart failure (95% CI 1.46-2.05); however demented patients were 0.56
times less likely to have hyperlipidemia (OR 0.56, 95% CI 0.47-0.66); 0.47
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times less likely to be obese (OR 0.47, 95% CI 0.30-0.74) and 0.33 times
less likely to be smokers or had ever smoked (OR 0.33, 95% CI 0.23-0.49).

There were no statistically significant differences between demented and no
demented patients in regards to hypertension (OR 0.9, 95% CI 0.76-1.08),
diabetes (OR 0.92, 95% CI 0.76-1.10), ESRD (OR 1.2, 95% CI 0.62-2.27),
alcohol abuse (OR 0.9, 95% CI 0.28-2.95) or COPD (OR 1.06, 95% CI 0.871.30). Refer to figure 4-16 for details of comorbidity for dementia patients.

% of STEMI patients with risk factor

Prevalence of common risk factors for STEMI patients by
dementia status
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*ESRD (End Stage Renal Disease), DEP (Depression), CKD (Chronic Kidney Disease), DM (Diabetes), CHF
(Congestive Heart Failure), HLP (Hyperlipidemia), HTN (hypertension).

Figure 4-16 Prevalence of common risk factors for STEMI patients by
dementia status.
88

4.5

Overview of Descriptive Statistics by Gender

Most of the cohort consisted of men, 56.7% (n=4726), yet most dements
were women (60%, n=362) and 1.2% more women than men had an
Alzheimer‟s diagnosis, 3.05% vs. 1.86% (OR 0.60, 95% CI 0.45-0.80).
Males were 1.9 times more likely than women to receive cardiac
catheterization (95% CI 1.69-2.08); 1.4 times more likely to be given PCI
(95% CI 1.27-1.53) and 2.2 times more likely to go through CABG (95% CI
1.89-2.64) (Figure 4-6).

Most men were in the early senior category and most women were in the mid
senior years, 54% and 40% respectively (Figure 4-17). Most white nonHispanic and Hispanics were males (56.4% and 61.8%), while most Black
non-Hispanics/African Americans were women (50.4%).

Percent of STEMI Patients

Age Distribution of Elderly STEMI Patients
by Gender
60%
50%
40%
30%

Males

20%

N=4726

10%
Females

0%

65-74 years old

75-84 years old

85+ years old

Age Categories

Figure 4-17 Age Distribution of STEMI Patients by Gender.
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Males were less likely to have strokes (OR 0.72, 95% CI 0.59-0.88),
hypertension (OR 0.75, 95% CI 0.68-0.83), depression (OR 0.41, 95% CI
0.33-0.50), CHF (OR 0.72, 95% CI 0.66-0.79) and COPD (OR 0.86, 95% CI
0.77-0.96) than women (Figure 4-18); but they were more likely to have
hyperlipidemia (OR 1.12, 95% CI 1.02-1.22) and chronic kidney disease (OR
1.26, 95%CI 1.11-1.43). Males were 4.2 times more likely to drink alcohol
than females (95% CI 1.86-9.34) and 1.3 times more likely to be smokers or
have a history of smoking (95% CI 1.45-1.49).

4.6

Multivariate Logistic Regression Analysis

4.6.1 Main Research Question
To address the main research question evaluating if there is a disparity in the
use of cardiac catheterization for ST-Myocardial Infarction patients with a
diagnosis of dementia versus patients without a diagnosis of dementia after
controlling for the following patient and hospital factors: age; gender;
ethnicity; zip code SES; year of hospital admission; hour of arrival at the
emergency department; source of admission; principal payer and the
following comorbidities: hypertension (HTN), diabetes mellitus type 2 (DM),
stroke (STRK), hyperlipidemia (HLP), obesity, smoking history (SMK),
depression (DEP), end stage renal disease (ESRD), chronic kidney disease
(CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease
(COPD) and chronic alcohol abuse (OH), models one, two and three were run
(Table 4-6).
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Model one addressed the probability of receiving diagnostic cardiac
catheterization among STEMI patients with and without dementia, not
adjusting for any other variables. A total of 8,331 observations were read; of
these 6,435 received diagnostic cardiac catheterization. Patients with a
diagnosis of dementia were less likely to receive catheterizations than
patients without dementia (OR 0.22; 95% CI 0.19-0.27, p<0.0001).

Only 93.5% (n=7791) of the cohort had Florida zip code data and
consequently had the proxy for zip code socio-economic status (SES). From
the available zip code SES data, the mean income of the cohort was
$35,086.30 (95% CI $30,865.5 - $39,307.0 p<0.0001). Demented patients
reported less income than non-demented ($29,471.40 vs. $35,532.30).

Model two adjusted for all variables of interest. There were 7,791
observations read and of these 5,985 received diagnostic cardiac
catheterization. After adjusting for all covariates, patients with dementia
were less likely to receive catheterizations than patients without dementia
(OR 0.41, 95% CI 0.34, 0.50; p<0.0001).

Model three did not adjust for zip code SES to see if there was a difference in
reducing the cohort by 540 observations and/or adjusting for this variable;
there were 8,331 observations read and 6,435 of these received cardiac
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catheterization. The only affected variable by excluding zip code SES from
model two was diabetes, which became statistically significant (OR 0.87;
95% CI 0.77-0.99; p=0.0324); all other variables remain unaffected.

Overall non-demented patients were 2.4 times more likely to receive
diagnostic cardiac catheterization than demented patients. Other conditions
that reduced the odds of receiving cardiac catheterization were: being
female; Black non-Hispanic ethnicity; having a stroke or having history of a
stroke; diagnosis of depression, CKD, CHF, or COPD. In addition, if a patient
was younger, had cardiovascular risk factors of hyperlipidemia, obesity and
was a current smoker, they were more likely to receive diagnostic cardiac
catheterization than if they did not. However, having hypertension and
drinking alcohol did not impact the outcome, nor did zip code SES, year of
admission, hour of arrival, source of admission to the hospital, method of
payment used, or having ESRD.
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Table 4-6 Results of Multivariate Logistic Regression for main research
question modeling the probability of diagnostic cardiac catheterization.

Dementia

Model One
(n=8331)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome
0.22 (0.19-0.27)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other

Model Two
(n=7791)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome
0.41 (0.34-0.50)

Model Three
(n=8831)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome
0.41 (0.34-0.50)

3.90 (3.31-4.58)
3.00 (2.59-3.48)
1.00

3.98 (3.40-4.66)
2.99 (2.59-3.45)
1.00

0.69 (0.61-0.77)
1.00

0.70 (0.62-0.78)
1.00

1.00
0.55 (0.43-0.71)
1.06 (0.88-1.28)

1.00
0.57 (0.44-0.73)
1.06 (0.89-1.04)

Zip code SES*
< $7750
≥$7750 <$30650
≥$30650

1.02 (0.87-1.21)
0.91 (0.78-1.05)
1.00

Year
2006
2007

0.94 (0.84-1.05)
1.00

0.93 (0.83-1.04)
1.00

0.83 (0.69-1.00)
1.00
0.91 (0.77-1.08)
0.78 (0.66-0.93)
0.82 (0.59-1.15)

0.85 (0.71-1.02)
1.00
0.92 (0.78-1.08)
0.77 (0.66-0.91)
0.81 (0.59-1.11)

1.08 (0.53-2.22)
0.99 (0.50-1.96)
1.00

1.16 (0.59-2.30)
1.04 (0.54-2.01)
1.00

1.21 (0.97-1.50)
1.13 (0.60-2.12)
1.00

1.18 (0.96-1.45)
0.97 (0.56-1.71)
1.00

Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown
Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**
Pay
Medicare
Self-Pay & Charity
Other***

Hypertension
1.02 (0.89-1.16)
0.99 (0.87-1.12)
Diabetes Type 2
0.90 (0.79-1.03)
0.87 (0.77-0.99)
Stroke
0.61 (0.48-0.77)
0.59 (0.47-0.75)
Hyperlipidemia
1.51 (1.34-1.70)
1.51 (1.35-1.70)
Obesity
1.51 (1.15-1.99)
1.50 (1.15-1.95)
Smoking
1.70 (1.38-2.11)
1.79 (1.45-2.21)
Depression
0.71 (0.56-0.89)
0.72 (0.57-0.90)
End Stage Renal Disease
0.87 (0.56-1.33)
0.86 (0.57-1.31)
Chronic Kidney Disease
0.61 (0.52-0.71)
0.62 (0.53-0.72)
Congestive Heart Failure
0.64 (0.57-0.73)
0.67 (0.59-0.75)
COPD
0.71 (0.62-0.82)
0.70 (0.61-0.80)
Chronic Alcohol abuse
1.14 (0.46-2.81)
1.03 (0.44-2.40)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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4.6.2 Secondary Research Questions
4.6.2.1 Secondary Question #1
Models four, five and six were run to determine if there was a difference in
PCI use between STEMI patients with and without dementia who underwent
cardiac catheterization compared to those who did not receive PCI but did
receive diagnostic cardiac catheterization. Only PCI was measured as
outcome for models 4 to 6; the models do not include patients who received
CABG. Model four was run without adjusting for any covariates, model five
adjusted for all covariates and model six adjusted for all covariates except
SES (Table 4-7).

After diagnostic cardiac catheterization, females were 1.4 times more likely
to receive PCI than males (95% CI 1.21-1.69; p <0.0001). Those patients
that belonged to a Florida zip code in which the average per capita income
was estimated to be less than $7,750 were 1.4 times more likely to receive
PCI. Also those with ESRD were more likely to undergo PCI (OR 2.66; 95%
CI 1.17-6.04). Patients who were diabetics, had strokes, presented CHF and
COPD were less likely to receive PCI. When the proxy for zip code SES was
eliminated for model six, ESRD was no longer statistically significant (OR
2.07; 95% CI 0.99-4.34; p=0531); nevertheless all other significant
variables in model five were still significant in model six.
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Table 4-7 Results of Multivariate Logistic Regression for secondary research
question #2 modeling the probability of receiving PCI for those patients that
received diagnostic cardiac catheterization.

Dementia

Model Four
(n=6435)
Odds Ratio (95% CI)
PCI as Outcome for
those who receive
catheterization
0.88 (0.63-1.24)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other
Zip code SES*
< $7750
≥$7750 <$30650
≥$30650
Year
2006
2007

Model Five
(n=5985)
Odds Ratio (95% CI)
PCI as Outcome for
those who receive
catheterization
0.92 (0.64-1.32)

Model Six
(n=6435)
Odds Ratio (95% CI)
PCI as Outcome for
those who receive
catheterization
0.92 (0.64-1.31)

0.66 (0.49-0.89)
0.61 (0.45-0.81)
1.00

0.65 (0.49-0.87)
0.59 (0.44-0.78)
1.00

1.43 (1.21-1.69)
1.00

1.48 (1.26-1.74)
1.00

1.00
0.96 (0.65-1.43)
0.92 (0.73-1.17)

1.00
0.98 (0.67-1.43)
1.00 (0.80-1.25)

1.38 (1.10-1.74)
1.01 (0.83-1.23)
1.00

Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown
Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**
Pay
Medicare
Self-Pay & Charity
Other***

0.99 (0.84-1.16)
1.00

0.97 (0.84-1.13)
1.00

0.99 (0.77-1.28)
1.00
1.03 (0.83-1.30)
1.06 (0.84-1.35)
0.94 (0.60-1.46)

1.0

0.38 (0.11-1.33)
0.48 (0.15-1.60)
1.00

0.33 (0.09-1.12)
0.46 (0.14-1.51)
1.00

0.997 (0.75-1.33)
0.95 (0.45-2.00)
1.00

1.0 (0.77-1.31)
0.99 (0.50-1.96)
1.00

(0.78-1.28)
1.00
1.02 (0.82-1.27)
1.07 (0.85-1.34)
0.97 (0.64-1.48)

Hypertension
0.93 (0.78-1.13)
0.93 (0.79-1.10)
Diabetes Type 2
0.70 (0.59-0.83)
0.72 (0.61-0.85)
Stroke
0.53 (0.38-0.72)
0.54 (0.40-0.74)
Hyperlipidemia
1.16 (0.99-1.37)
1.18 (1.01-1.37)
Obesity
0.82 (0.62-1.08)
0.78 (0.59-1.01)
Smoking
1.28 (1.00-1.63)
1.23 (0.97-1.54)
Depression
0.78 (0.56-1.08)
0.77 (0.56-1.06)
End Stage Renal Disease
2.66 (1.17-6.04)
2.07 (0.99-4.34)
Chronic Kidney Disease
0.81 (0.64-1.02)
0.83 (0.67-1.04)
Congestive Heart Failure
0.39 (0.33-0.47)
0.38 (0.33-0.45)
COPD
0.69 (0.57-0.83)
0.69 (0.57-0.82)
Chronic Alcohol abuse
1.16 (0.43-3.12)
1.26 (0.47-3.37)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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4.6.2.2 Secondary Question #2
Models seven, eight and nine run to ascertain if there was a disparity of
CABG use between STEMI patients with and without dementia who
underwent cardiac catheterization compared to those who did not receive
CABG but did receive diagnostic cardiac catheterization (Table 4-8).

Model seven did not adjust for any covariates; model eight adjusted for all
covariates and model nine adjusted for all covariates except zip code SES;
but this did not produce any statistically significant change. Overall younger
patients are more likely to undergo CABG than older patients as well as
patients with diabetes, strokes, obesity, CKD, CHF and COPD. On the other
hand females, those in the lower SES and with end stage renal disease, were
less likely to undergo CABG than those patients that were males and did not
have the mentioned comorbidities. For complete results see table 4-8.
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Table 4-8 Results of Multivariate Logistic Regression for secondary research
question #3 modeling the probability of receiving CABG for those patients
that received diagnostic cardiac catheterization.

Dementia

Model Seven
(n=6435)
Odds Ratio (95% CI)
CABG as Outcome
for those who receive
catheterization
0.64 (0.41-0.99)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other
Zip code SES*
< $7750
≥$7750 <$30650
≥$30650
Year
2006
2007

Model Eight
(n=5985)
Odds Ratio (95% CI)
CABG as Outcome
for those who receive
catheterization
0.74 (0.46-1.20)

Model Nine
(n=6435)
Odds Ratio (95% CI)
CABG as Outcome
for those who receive
catheterization
0.74 (0.47-1.17)

3.21 (2.14-4.82)
2.83 (1.89-4.23)
1.00

3.18 (2.15-4.70)
2.85 (1.93-4.20)
1.00

0.52 (0.43-0.63)
1.00

0.52 (0.43-0.62)
1.00

1.00
0.85 (0.55-1.32)
1.05 (0.81-1.36)

1.00
0.87 (0.58-1.32)
0.96 (0.75-1.21)

0.59 (0.46-00.75)
0.92 (0.75-1.13)
1.00

Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown
Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**
Pay
Medicare
Self-Pay & Charity
Other***

0.95 (0.80-1.12)
1.00

0.92 (0.79-1.08)
1.00

1.01 (0.77-1.31)
1.00
0.96 (0.76-1.21)
0.74 (0.57-0.96)
1.20 (0.75-1.92)

1.00 (0.77-1.92)
1.00
0.98 (0.79-1.22)
0.74 (0.58-0.95)
1.11 (0.71-1.73)

1.42 (0.47-4.34)
1.45 (0.51-4.17)
1.00

1.74 (0.58-5.22)
1.49 (0.52-4.23)
1.00

0.93 (0.70-1.24)
1.22 (0.59-2.50)
1.00

0.91 (0.70-1.19)
0.98 (0.50-1.93)
1.00

Hypertension
1.05 (0.87-1.26)
1.02 (0.86-1.22)
Diabetes Type 2
1.32 (1.10-1.58)
1.28 (1.08-1.52)
Stroke
1.88 (1.33-2.65)
1.79 (1.29-2.49)
Hyperlipidemia
0.92 (0.77-1.10)
0.89 (0.75-1.04)
Obesity
1.51 (1.15-1.99)
1.50 (1.15-1.96)
Smoking
0.91 (0.71-1.16)
0.94 (0.75-1.18)
Depression
1.16 (0.79-1.68)
1.18 (0.83-1.69)
End Stage Renal Disease
0.37 (0.15-0.90)
0.34 (0.14-0.82)
Chronic Kidney Disease
1.42 (1.11-1.82)
1.46 (1.16-1.84)
Congestive Heart Failure
1.96 (1.63-2.36)
1.97 (1.66-2.34)
COPD
1.39 (1.13-1.69)
1.38 (1.14-1.67)
Chronic Alcohol abuse
1.06 (0.42-2.67)
0.99 (0.40-2.45)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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4.6.2.3 Secondary Question #3
Models ten through fifteen were run to determine if there was a difference
between the days to procedure (PCI or CABG) for STEMI patients with and
without dementia (Tables 4-9, 4-10)

Models 10-12 evaluated same day PCI. Model 10 calculated the probability of
same day PCI for STEMI patients with and without dementia. Model 11
assessed the probability of same day PCI for those patients that received
diagnostic cardiac catheterization with and without dementia. Model 12 is
based on model ten but adjusts for all covariates of interest.
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Table 4-9 Results of Multivariate Logistic Regression models for secondary
research question #3 modeling the probability of same day PCI for STEMI
patients.
Model ten
(n=7791)
Odds Ratio (95% CI)
Same day PCI as
Outcome
Dementia

0.34 (0.29-0.41)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other
Zip code SES*
< $7750
≥$7750 <$30650
≥$30650

Model Eleven
(n=6435)
Odds Ratio (95% CI)
Same day PCI as
Outcome for those who
receive catheterization
0.93 (0.71-1.24)

Model Twelve
(n=7791)
Odds Ratio (95% CI)
Same day PCI as
Outcome
0.53 (0.44-0.64)
2.25 (1.94-2.61)
1.87 (1.63-2.15)
1.00
0.97 (0.88-1.07)
1.00
1.00
0.66 (0.53-0.83)
0.98 (0.84-1.15)
1.11 (0.96-1.28)
0.95 (0.84-1.07)

Year
2006
2007

0.89 (0.81-0.99)
1.00

Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown

0.85 (0.73-1.00)
1.00
0.95 (0.83-1.09)
0.79 (0.68-0.91)
0.83 (0.63-1.10)

Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**
Pay
Medicare
Self-Pay & Charity
Other***

1.09 (0.60-1.98)
1.08 (0.61-1.89)
1.00
1.03 (0.86-1.23)
1.03 (0.62-1.70)
1.00

Hypertension
0.94 (0.84-1.05)
Diabetes Type 2
0.74 (0.66-0.83)
Stroke
0.54 (0.43-0.68)
Hyperlipidemia
1.30 (1.18-1.44)
Obesity
1.05 (0.86-1.29)
Smoking
1.55 (1.32-1.82)
Depression
0.70 (0.57-0.87)
End Stage Renal Disease
1.39 (0.92-2.08)
Chronic Kidney Disease
0.60 (0.52-0.69)
Congestive Heart Failure
0.48 (0.43-0.53)
COPD
0.66 (0.59-0.75)
Chronic Alcohol abuse
1.16 (0.59-2.30)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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Overall, if a patient had dementia they were less likely to receive PCI within
the first twenty four hours than someone who did not have dementia (OR
0.34, 95% CI 0.29-0.41). This was still statistically significant after adjusting
for all covariates of interest. When potential confounders were adjusted,
being younger, hyperlipidemic and a smoker placed the patient at better
odds of receiving same day PCI; while if the patient was Black/AfricanAmerican non-Hispanic, hypertensive, had a stroke or had a history of
stroke, depression, CKD, CHF and COPD they were less likely to receive same
day PCI. Model eleven was run for those who received diagnostic cardiac
catheterization without adjusting for any covariates, having dementia was
not statistically significant for receiving same day PCI.

To evaluate same day CABG, modes 13-15 were run. Model 13 appraised the
probability of same day CABG for STEMI patients with and without dementia
compared to those STEMI patients with and without dementia who did not
receive same day CABG. Model 14 assessed the probability of same day
CABG for those STEMI patients with and without dementia who received
diagnostic cardiac catheterization compared to those STEMI patients with and
without dementia who did not receive same day CABG and model 15 is
based on model thirteen but adjusts for all covariates of interest; refer to
table 4-10.
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Table 4-10 Results of Multivariate Logistic Regression models for secondary
research question #3 modeling the probability of same day CABG for STEMI
patients.
Model thirteen
(n=7791)
Odds Ratio (95% CI)
Same day CABG as
Outcome
Dementia

0.45 (0.27-0.76)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other

Model fourteen
(n=6435)
Odds Ratio (95% CI)
Same day CABG as
Outcome for those who
receive catheterization
0.871 (0.52-1.46)

Model fifteen
(n=7791)
Odds Ratio (95% CI)
Same day CABG as
Outcome
0.69 (0.40-1.18)
3.50 (2.21-5.51)
2.94 (1.18-4.62)
1.00
0.50 (0.39-0.63)
1.00
1.00
0.82 (0.48-1.41)
1.17 (0.86-1.59)

Zip code SES*
< $7750
≥$7750 <$30650
≥$30650

0.80 (0.59-1.07)
0.96 (0.74-1.24)
1.00

Year
2006
2007
Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown

1.05 (0.86-1.29)
1.00
0.74 (0.53-1.03)
1.00
0.90 (0.69-1.19)
0.52 (0.37-0.73)
0.73 (0.41-1.27)

Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**
Pay
Medicare
Self-Pay & Charity
Other***

1.33 (0.38-4.63)
0.86 (0.26-2.83)
1.00
1.13 (0.78-1.62)
1.27 (0.51-3.15)
1.00

Hypertension
1.01 (0.81-1.27)
Diabetes Type 2
0.98 (0.78-1.23)
Stroke
1.60 (1.06-2.41)
Hyperlipidemia
0.90 (0.73-1.11)
Obesity
1.38 (0.97-1.96)
Smoking
0.84 (0.62-1.15)
Depression
1.14 (0.72-1.79)
End Stage Renal Disease
0.34 (0.08-1.44)
Chronic Kidney Disease
0.79 (0.57-1.10)
Congestive Heart Failure
1.49 (1.18-1.87)
COPD
1.38 (1.08-1.75)
Chronic Alcohol abuse
0.60 (0.14-2.56)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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Patients with dementia were much less likely to receive CABG within the first
twenty four hours than someone who did not have dementia (OR 0.45, 95%
CI 0.27-0.76). However when potential confounders were adjusted for this
effect was not statistically significant. Being younger, hyperlipidemic, having
COPD or CHF placed the patient at better odds of receiving same day CABG;
whereas if the patient was a female or was admitted at night, versus the
morning, they were less likely to receive same day CABG. When model
fourteen was run for those who received diagnostic cardiac catheterization
without adjusting for any covariates, having dementia was not statistically
significant for receiving same day CABG.

4.6.2.4 Secondary Question #4
Models sixteen through nineteen were constructed to identify if having
dementia affected the length of hospital stay for STEMI patients (Table 411).

To best evaluate this time-dependent variable a Cox regression analysis was
conducted only on STEMI patients with and without dementia who survived
the hospital stay. Although Cox regression assumes that the hazards of the
comparison groups are proportional, this model fits the data better than a
logistic regression model. Model sixteen is unadjusted, model seventeen
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adjusts for all covariates of interest and model eighteen adjusts for all
variables except zip code SES.

In model 16, the hazard ratio assumed that the exposure of STEMI patients
to length of hospital stay is multiplicative of some underlying hazard, in this
case dementia. The result showed that patients with dementia had longer
length of hospital stay than patients without dementia (hazard ratio=0.90,
p=0.0203). When all covariates of interest where added in model seventeen,
the predictability of dementia became statistically insignificant (hazard
ratio=1.0, p=0.9667) indicating that one of the covariates was highly
correlated with the dementia factor. However when the correlations were
analyzed in the basic model 2, there were no strong correlations of any one
variable with dementia.

After adjusting for all variables of interest in model 17, patients 75-84 years
of age and Black/African American non-Hispanics had a significantly lower
hazard of being released from the hospital on any day of their stay than
those patients without dementia (Table 4-11); also those who arrived at
night had significantly lower hazard of being discharged (hazard ratio=0.928,
p=0.0352) compared to those that arrived in the morning hours.
Comorbidities such as diabetes, current or history of stroke, hyperlipidemia,
obesity, smoking, depression, chronic kidney disease, congestive heart
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failure, chronic obstructive pulmonary disease and chronic alcohol abusers
also had lower hazard of being released from the hospital than those without
those conditions. However, patients with hyperlipidemia and current or
history of smoking had significantly higher hazard of being discharged from
the hospital than those without hyperlipidemia or positive smoking status.
When model eighteen was run without adjusting for SES, there were no
changes from model seventeen indicating that SES was not a confounder on
the previously stated associations.
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Table 4-11 Results of Cox regression analysis for secondary research
question #4 modeling length of hospital stay for STEMI patients.

Dementia

Model sixteen
(n=7422)
Hazard Ratio (p)
for STEMI survivors
0.898 (p=0.0203)

Age Category
65-74
75-84
85+
Gender
Female
Male
Ethnicity
White non-Hispanic
Black non-Hispanic
Hispanic/Other

Model seventeen
(n=7422)
Hazard Ratio (p)
for STEMI survivors
0.998 (p=0.9667)

Model eighteen
(n=7422)
Hazard Ratio (p)
for STEMI survivors
1.002 (p=0.9608)

1.002(p=0.9601)
0.914 (p=0.0147)
1.00

0.994 (p=0.8784)
0.905 (p=0.0054)
1.00

0.993 (p=0.7672)
1.00

0.996 (p=0.8688)
1.00

1.00
0.877 (p=0.0229)
1.028 p=(0.4718)

1.00
0.873 (p=0.0161)
1.026 (p=0.4906)

Zip code SES*
< $7750
≥$7750 <$30650
≥$30650

1.016 (p=0.6502)
1.036 (p=0.2566)
1.00

Year
2006
2007

0.995 (p=0.8211)
1.00

0.997 (p=0.8905)
1.00

1.007 (p=0.8524)
1.00
0.991 (p=0.7839)
0.928 (p=0.0352)
1.018 (p=0.8092

1.007 (p=0.8555)
1.00
0.986 (p=0.6784)
0.931 (p=0.0391)
1.054 (p=0.4424)

Source of Admission
Outside Hospital MD Ref
Emergency Room MD Ref
Other**

0.993 (p=0.9666)
1.029 (p=0.8426)
1.00

0.934 (p=0.6514)
1.028 (p=0.8424)
1.00

Pay
Medicare
Self-Pay & Charity
Other***

0.967 (p=0.4455)
0.818(p=0.1043)
1.00

0.989 (p=0.7916)
0.860 (p=0.1818)
1.00

Hour of arrival to hospital
Early Morning
Morning
Afternoon
Night
Unknown

Hypertension
0.973 (p=0.3110)
0.986 (p=0.6015)
Diabetes Type 2
0.914 (p=0.0012)
0.916 (p=0.0011)
Stroke
0.683 (p<0.0001)
0.681 (p<0.0001)
Hyperlipidemia
1.122 (p<0.0001)
1.125 (p<0.0001)
Obesity
0.894 (p=0.0201)
0.901 (p=0.0277)
Smoking
1.110 (p=0.0054)
1.104 (p=0.0060)
Depression
0.843 (p=0.0012)
0.840 (p=0.0007)
End Stage Renal Disease
0.841 (p=0.1413)
0.834 (p=0.1186)
Chronic Kidney Disease
0.728 (p<0.0001)
0.717 (p<0.0001)
Congestive Heart Failure
0.509 (p<0.0001)
0.506 (p<0.0001)
COPD
0.809 (p<0.0001)
0.806 (p<0.0001)
Chronic Alcohol abuse
0.697 (p=0.0242)
0.712 (p=0.0280)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.)
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4.7

Sensitivity Analysis

A sensitivity analysis was carried out to determine if it is appropriate or not
to use the broad definition of dementia compared to the strict or more
specific definition of Alzheimer‟s disease. Table 4-12 compares the three
models used. All models are based on 7,791 observations with proxy data for
SES modeling the probability of receiving diagnostic cardiac catheterization.

General model two was used as the comparison since it used the broad
definition of dementia. Model 19 used the same 7,991 observations as model
two but the definition of dementia was restricted to only those that had
dementia type Alzheimer‟s and model 20 looked at those patients that had
dementia but not a diagnosis of Alzheimer‟s disease.

The results obtained from all three models (refer to table 4-12) showed that
there were no statistically significant differences between using the broad
definition of dementia compared to the more strict definition of Alzheimer‟s
disease when testing diagnostic cardiac catheterization as the outcome.
However when exposure is limited only to those patients with Alzheimer‟s
diagnosis, the effect of dementia is slightly stronger (OR 0.38, 95% CI 0.280.52) compared to the effect for all demented patients (OR 0.41, 95% CI
0.34-0.50).
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Table 4-12 Results of sensitivity analysis evaluating the broad definition of
dementia versus the definition of Alzheimer‟s disease.
Model two
(n=7791)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome Where
Exposure is
Dementia◊
0.41 (0.34-0.50)

Model Nineteen
(n=7791)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome Where
Exposure Dementia
AD◊
0.38 (0.28-0.52)

Model twenty
(n=7791)
Odds Ratio (95% CI)
Diagnostic Cardiac
Catheterization as
Outcome Where
Exposure is
Dementia non-AD◊
0.44 (0.35-0.56)

Dementia
Age Category
65-74
3.90 (3.31-4.58)
4.30 (3.67-5.04)
3.81 (3.23-4.49)
75-84
3.00 (2.59-3.48)
3.20 (2.77-3.70)
2.96 (2.55-3.44)
85+
1.00
1.00
1.00
Gender
Female
0.69 (0.61-0.77)
0.68 (0.60-0.76)
0.67 (0.59-0.76)
Male
1.00
1.00
1.00
Ethnicity
White non-Hispanic
1.00
1.00
1.00
Black non-Hispanic
0.55 (0.43-0.71)
0.54 (0.42-0.69)
0.55 (0.43-0.71)
Hispanic/Other
1.06 (0.88-1.28)
1.07 (0.88-1.29)
1.08 (0.89-1.31)
Zip code SES*
< $7750
1.02 (0.87-1.21)
1.00 (0.85-1.18)
1.02 (0.86-1.21)
≥$7750 <$30650
0.91 (0.78-1.05)
0.89 (0.77-1.03)
0.92 (0.79-1.07)
≥$30650
1.00
1.00
1.00
Year
2006
0.94 (0.84-1.05)
0.95 (0.84-1.06)
0.95 (0.84-1.07)
2007
1.00
1.00
1.00
Hour of arrival to hospital
Early Morning
0.83 (0.69-1.00)
0.82 (0.68-0.99)
0.83 (0.68-1.00)
Morning
1.00
1.00
1.00
Afternoon
0.91 (0.77-1.08)
0.90 (0.77-1.07)
0.93 (0.78-1.09)
Night
0.78 (0.66-0.93)
0.79 (0.67-0.93)
0.80 (0.67-0.95)
Unknown
0.82 (0.59-1.15)
0.82 (0.59-1.14)
0.81 (0.58-1.13)
Source of Admission
Outside Hospital MD Ref
1.08 (0.53-2.22)
1.11 (0.54-2.25)
1.04 (0.49-2.21)
Emergency Room MD Ref
0.99 (0.50-1.96)
0.98 (0.50-1.93)
0.94 (0.46-1.92)
Other**
1.00
1.00
1.00
Pay
Medicare
1.21 (0.97-1.50)
1.20 (0.97-1.50)
1.20 (0.96-1.49)
Self-Pay & Charity
1.13 (0.60-2.12)
1.14 (0.61-2.14)
1.16 (0.61-2.21)
Other***
1.00
1.00
1.00
Hypertension
1.02 (0.89-1.16)
1.03 (0.90-1.17)
1.01 (0.88-1.15)
Diabetes Type 2
0.90 (0.79-1.03)
0.90 (0.79-1.02)
0.89 (0.78-1.02)
Stroke
0.61 (0.48-0.77)
0.60 (0.47-0.76)
0.60 (0.47-0.77)
Hyperlipidemia
1.51 (1.34-1.70)
1.52 (1.35-1.70)
1.47 (1.30-1.65)
Obesity
1.51 (1.15-1.99)
1.52 (1.16-2.00)
1.57 (1.18-2.07)
Smoking
1.70 (1.38-2.11)
1.72 (1.39-2.12)
1.73 (1.39-2.14)
Depression
0.71 (0.56-0.89)
0.67 (0.53-0.84)
0.72 (0.57-0.92)
End Stage Renal Disease
0.87 (0.56-1.33)
0.87 (0.56-1.33)
0.86 (0.56-1.32)
Chronic Kidney Disease
0.61 (0.52-0.71)
0.61 (0.52-0.72)
0.60 (0.51-0.70)
Congestive Heart Failure
0.64 (0.57-0.73)
0.64 (0.57-0.72)
0.64 (0.57-0.73)
COPD
0.71 (0.62-0.82)
0.70 (0.61-0.81)
0.69 (0.60-0.79)
Chronic Alcohol abuse
1.14 (0.46-2.81)
1.14 (0.46-2.80)
1.62 (0.56-4.71)
* Zip Code Socio-Economic Status **Other:Transfer from skilled nursing facility; court/law enforcement;
information not available) ***Other (any other method of payment: Medicaid,commercial insurance;
worker‟s compensation, CHAMPUS; VA; Other State/Local Government; Other.) ◊Model 2 had 591
patients with dementia; model 19 had 190 AD patients, and model 20 had 401 dementia non-AD patients.
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CHAPTER 5
DISCUSSION

5.1 Findings
Results obtained indicate that demented STEMI patients are less likely to
receive diagnostic cardiovascular catheterizations than non-demented
patients, even after controlling for potential confounding factors. This finding
is consistent with that from Sloan et al. (2004)(78). Results from this study
indicate that demented patients are 0.4 times less likely to receive diagnostic
cardiac catheterization than non demented patients while Sloan et al.
(2004)(78) estimated the risk ratio at 0.5. The 95% confidence intervals for
both studies overlapped (0.34-0.50 vs. 0.47-0.55).

Models two and three also showed that being female or Black/African
American non-Hispanic reduced the odds of receiving diagnostic cardiac
catheterization compared to males and those White-non-Hispanic; the AHA
and many studies in the literature support this result(3, 7, 66, 83).
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Black African American non-Hispanics were 0.5 times less likely to receive
diagnostic cardiac catheterization than White non-Hispanics. Yet, the odds of
receiving PCI or CABG for those Black African American non-Hispanics that
did receive diagnostic cardiac catheterization became statistically insignificant
once patient and hospital factors were taking into account. Nonetheless,
when measuring the probability of receiving same day PCI, Blacks were 0.7
times less likely to have same day PCI than Whites. Similar results were
obtained in earlier analysis done by Pathak and Strom (2008)(66).

Arriving to the hospital at night also seems to place patients at worse odds of
receiving diagnostic cardiac catheterization. The analysis also suggests that
being admitted to the hospital at night places patients at worse odds to
receive treatment (PCI or CABG) within the first 24 hours than those who
arrived in the morning. Arriving at night was also associated with having
longer hospital stay than patients who arrived in the morning. Studies show
that arriving at night or off-hours are associated with higher in patient
mortality and longer time to treatment(84) .

When the socio-economic variable was not accounted for while evaluating the
use of diagnostic cardiac catheterizations among STEMI patients, the only
variable affected was diabetes; however the effect was marginal given that
the upper confidence interval was 0.99. Earlier studies showed that cultural
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factors are a stronger indication of diabetes outcomes(85) than SES but most
current literature indicate that patients from lower SES have a much higher
and disproportionate prevalence of diabetes(86-88). Some studies suggest
that measuring a combination of SES factors can be a more sensitive method
to measure outcome disparities. In this study SES was directly measured by
the proxy of mean zip code income for each observation in the dataset and it
was also indirectly measured by controlling for type of payment used in the
hospital; however the type of payment used was not a statistically significant
variable for any of the results obtained.

Regardless of accounting or not for SES, STEMI patients with comorbidities
such as having a stroke or having history of a stroke, having diabetes, CKD,
CHF, COPD and a diagnosis of depression made them less likely to receive
diagnostic cardiac catheterizations. This may be partially explained by
physical reasons; COPD or CHF patients may not be able to tolerate supine
positions without undergoing general anesthesia and thus may be more likely
to receive alternative reperfusion treatments and some patients with
advanced chronic kidney disease may not tolerate the use of any contrast in
diagnostic cardiac catheterization.

The results of table 4-6 indicate that patients who were younger, obese,
hyperlipidemic, smokers or having had history of being smokers were more
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likely to receive diagnostic cardiac catheterizations. However these
characteristics were not statistically significant for receiving PCI after
undergoing cardiac catheterization. In contrast, smokers who were
catheterized were more likely to receive CABG than non-smokers who did
receive catheterization. This may be explained by the smoker‟s paradox.
Studies have demonstrated that STEMI patients who smoke have better
myocardial perfusion than non-smoker STEMI patients after undergoing
myocardial reperfusion(89). The results obtained in this study suggest that
smokers who were catheterized were more likely to receive CABG than PCI;
this difference could be dependent on the number of vessel damage the
STEMI smokers presented compared to non-smoker STEMI patients.

After controlling for patient and hospital factors, those older than 85 years of
age were less likely to receive diagnostic cardiac catheterization than
younger patients. Nonetheless, from the 50% of patients over 85 years of
age who did receive diagnostic cardiac catheterization, these were more
likely to receive PCI than the younger cohorts who received diagnostic
cardiac catheterization. Since 2004, the American Heart Association Practice
Guidelines for STEMI patients have indicated primary PCI as first line of
treatment for STEMI patients (Class I for those younger than 75 years of age
and Class IIa in STEMI patients older than 75 years)(4, 68) , thus these
results suggest that for the years 2006-2007 the guidelines were met for half
of the patients over 85 years of age living in Florida at the time of their
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STEMI. Nevertheless, patients 65-74 years old were 3.2 times more likely to
undergo CABG than those older than 85. Although there may be medical
and/or anatomical reasons for this outcome, the ACC/AHA Practice Guidelines
have suggested that this may be due to surgeons coming under public
scrutiny with regards to mortality rates(4).

There was no statistically significant difference in the use of PCI between
non-demented and demented patients who had already undergone diagnostic
cardiac catheterization. Individuals from lower income areas or those with
end stage renal disease seem to receive more PCI than their counterparts
after initial diagnostic catheterization. A negative disparity in receiving PCI
after initial catheterization was observed in patients with a diagnosis of
diabetes, stroke, congestive heart failure and COPD after adjustment for
patient and hospital factors.

Female patients were 0.7 times less likely to receive diagnostic cardiac
catheterization than males after controlling for potential confounders. Yet if
they were catheterized, women were 40% more likely to receive PCI than
men. Opposite results were reported by Hirakawa et al. (2006)(79); their
study looked at the effect of emergency PCI on in hospital mortality in elderly
patients with AMI and found that female patients received fewer PCIs. Just
like Sloan et al.(78), Hirakawa et al.(79) looked at all AMI instead of just
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STEMI, therefore their results are less specific than those obtain in this
study.

Results from this study suggest that there was still a disparity by gender for
more aggressive therapy; females were 0.5 times less likely than males to
undergo CABG after receiving diagnostic catheterization and 0.5 times less
likely to receive it within the first 24 hours after hospital admission than
males.

Demented STEMI patients who underwent diagnostic cardiac catheterization
were less likely to receive CABG than those non-demented; however the
effect disappeared when covariates were added to the model. CABG results
from this study contrasted with those of Sloan et al. (2004) who found a
statistically significant difference between demented and non demented
patients even after adjustment. This may be attributable to several factors
including the different potential confounding factors controlled for in both
studies. The difference may also account to the fact that this study
specifically evaluated STEMI patients while Sloan et al. evaluated acute
myocardial infarctions (AMI) in general.
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When evaluating the AHA guidelines for the timing of PCI, older patients
were much less likely to receive same-day PCI or same-day CABG than
younger patients. This result is consistent with that obtained from Pathak &
Strom (2008)(66) for the years 2001-2005 in Florida. However, it is
important to note that patients with prior CABG, females and the elderly
have a higher risk of mortality if the CABG is performed early after the STEMI
which may explain this disparity. The AAC/AHA Guidelines from 2004 indicate
that STEMI patients have an elevated mortality from CABG if performed in
the first 3 to 7 days after the MI(4).

After adjusting for all variables of interest, socio-economic disparities were
only statistically significant for those patients undergoing CABG. A study by
Bernheim et al. (2007) (67) showed a trend towards lower SES groups
receiving fewer quality-of-care measures, however they did not report
measures for CABG.

A Cox regression analysis was performed to evaluate the length of hospital
stay for STEMI patients with and without dementia. When patient factors
were not added into the model, patients without dementia had significantly
shorter length of hospital stay than patients with dementia. However when
other factors were added into the model, this effect disappeared. Further
analysis is needed to determine if there is an interaction effect of some
comorbidities with dementia.
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In order to clarify if the dementia definition used in this study was
appropriate or if a stricter definition such Alzheimer‟s should have been used,
a sensitivity analysis of the definition was conducted based on the main
study model. The results obtained demonstrate that when exposure is limited
to those with Alzheimer‟s the effect of dementia is slightly stronger than
when the general definition is implemented. However, overall using the
general definition did not statistically affect the outcome, in this case
diagnostic cardiac catheterization. These results suggest that the disparity in
outcomes for demented patients is dependent on the perception of medical
personnel in the emergency department towards those with dementia.
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5.2 Strengths and Limitations of the Study
One of the main strengths of this study is that it is based on the
comprehensive population coverage of Florida‟s hospital discharge database
with little information bias. However it does bring in some uncontrollable
limitations. First, the dataset includes only patients admitted to high volume
PCI Florida hospitals with a STEMI diagnosis, therefore external validity is not
applicable outside this strict definition.

Underreporting of risk factors is also expected given the nature of the
medical emergency under study (STEMI) and the coding procedures used,
consequently some nondifferential misclassification may exist that may bias
results toward the null. It is also impossible to determine how dementia was
measured by the hospital staff. With this data temporality cannot be
determined, whether the dementia code was written in the chart when the
patient was admitted to the hospital affecting directly the outcome
dependent on the exposure; or if dementia was coded later during the
hospitalization after interviewing the patient or the family further, in this case
not having affected the outcome directly.

The underlying severity of the coronary condition of each of these patients
cannot be measured directly and as a result this study does not adjust for it,
nor does it account for previous cardiovascular procedures performed. Some
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patients with multi-vessel disease or who had previous interventions may not
have received PCI because it was not the optimal treatment while CABG was.
On the other hand, patients with low left ventricular function,
hemodinamically unstable or with high risk comorbidities may have had
further indications to wait until stabilization to proceed with CABG. This
limitation was not accounted for when days to procedure was measured. It is
also important to mention that the variable „days to procedure‟ was only
measured as a dichotomous variable, the procedure was either performed in
the first 24 hours or it was not; the purpose was to capture the adherence to
the ACC/AHA STEMI guidelines for PCI in STEMI patients.

The use of average per capita income by zip code as proxy for socioeconomic status is an imperfect surrogate for individual level data. SES is an
ecological variable therefore it only measures income per residential area; it
is not a true estimate of the financial condition of the patients. Another
frequently used SES measure is the method of hospital payment which was
also adjusted for in this study; however this measure is also limited and does
not provide significant information given that most of the elderly population
has Medicare.

When comorbidities were adjusted, the potential for over adjustment may be
present. For example, depression is a prodromal symptom for dementia.
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Obesity, hypertension, hyperlipidemia, depression and diabetes are all
components of the metabolic syndrome, thus adjustment as a group may
have yielded a different outcome.

There may be some unmeasured residual confounding by the patient‟s age or
hospital level that was not accounted for in this study. Even though age was
a variable that was adjusted for in the study, it is well known that on average
females outlive males, therefore some unmeasured effect may be left
unaccounted for.

Last but certainly not least, the data used does not contain specific codes for
treatment refusal from the patients, their families or health care
surrogates/proxies which may influence the results in this study. It is very
common for very elderly patients in Florida to have “Do not resuscitate”
(DNR) forms, which specify for CPR to be withheld or withdrawn in case of a
myocardial infarction; they may have advanced directives, which specify
their wishes upon a medical emergency; or they may have a living will in
which they specify their healthcare wishes that may include to not receive
therapy. By Florida law, patients with advanced dementia who do not have
advanced directives or DNRs, their spouse or next-in- kin automatically
acquire the legal authorized representative status and they may make the
medical decisions for the demented patient.
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Other studies known (41, 78, 79, 90) have measured the effect of dementia
on the use of PCI as a secondary outcome. A similar study to the one
presented here was done by Sloan et al. in 2004; they measured the
cardiovascular outcomes of Medicare beneficiaries but the population in that
study included all kinds of Acute Myocardial Infarctions. This study uses a
more specific approach in accordance with the ACC/AHA guidelines; PCI is
specifically indicated for STEMI patients not non-STEMI. Thus despite all the
mentioned limitations, this is the first known study to date that has directly
measured the effect of dementia on the use of diagnostic cardiac
catheterization among STEMI patients in Florida.
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5.3 Future Research
Further studies are needed to measure the impact of dementia on the quality
of medical care received by dementia patients, especially in emergency
settings. The need to include ways of measuring the legal aspect of the
medical decisions for demented patients in epidemiological studies also
requires further evaluation.

A closer look at treatment disparities for demented ethnic minorities and
women is urgently needed in order to adequately allocate resources and
narrow the disparities.

Evaluating other exposures within different groups by ethnicity, gender or
medical condition in this cohort may better explain some of the results. For
example knowing which women were previously exposed to hormone
replacement therapy and who were not may enhance the results obtained by
explaining the contrasting results for women undergoing catheterization and
PCI versus CABG for both demented and non-demented female patients.

Enhancing the analysis performed in this study by perhaps including hospital
level effects and geographical patterns in the statistical analysis may be able
to determine trends that can help decrease the gap in treatment disparities
in Florida. An appraisal of medications and the temporality of the diagnostic
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codes received by these patients may also help to better understand the
results.

Even though the AHA has helped improved the outcomes for STEMI patients
in the last few years, it still does not have specific guidelines or algorithms
for emergency personnel to follow when encountering elderly patients;
therefore a national appraisal of disparities in treatment is urgently needed
to not only narrow the gaps in treatment for elderly patients but those with
dementia as well.

5.4 Conclusion
This study provides evidence that dementia is a limiting factor for receiving
diagnostic cardiac catheterization after a STEMI. Results from this research
coincide with many reported in the literature of outcomes research; women,
the elderly and Black African American non-Hispanics are still subject to
disparities, in this case diagnostic cardiac catheterization.
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Appendix 1. Summary of recommendations from the American College of
Cardiology and the American Heart Association for the management of
STEMI, pg.e104 (4)

Figure 7. Major components of time delay between onset of symptoms from ST-elevation MI and restoration
of flow in the infarct artery. Plotted sequentially from left to right are shown the time for patients to recognize
symptoms and seek medical attention, transportation to the hospital, in-hospital decision-making, and
implementation of reperfusion strategy, in time for restoration of flow once the reperfusion strategy has been
initiated. The time to initiate fibrinolytic therapy is the "door-to-needle" (D-N) time; this is followed by the
period of time required for pharmacologic restoration of flow. More time is required to move the patient to the
catheterization laboratory for a percutaneous coronary interventional (PCI) procedure, referred to as the
"door-to-balloon" (D-B) time, but restoration of flow in the epicardial infarct artery occurs promptly after PCI.
At the bottom are shown a variety of methods for speeding the time to reperfusion along with the goals for
the time intervals for the various components of the time delay. Cath= catheterization; PCI = percutaneous
coronary intervention; min = minutes; ECG = electrocardiogram; MI = myocardial infarction; Rx = therapy.
*These bar graphs are meant to be semiquantitative and not to scale. Modified with permission from Cannon
et al. J Thromb Thrombol 1994;1:27-34 (180).
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Appendix 2. Applying Classification of Recommendations and Level of
Evidence pg.e87(4).
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Appendix 3. ICD-9 CM Coding Use for Comorbity
HYPERTENSION:
401.0 is malignant essential HTN,
401.1 is benign essential HTN and
401.9 = essential HTN unspecified
403 = Hypertensive chronic kidney disease
403.0= Malignant
403.01= Malignant
403.10 = Benign
403.11 = Benign
403.9 =Unspecified
403.90 =Unspecified
403.91 =Unspecified
DIABETES:
250 Diabetes mellitus
250.0 Diabetes mellitus without mention of complication [0-3]
Diabetes mellitus without mention of complication or
manifestation classifiable to 250.1-250.9
Diabetes (mellitus) NOS 250.1
Diabetes with ketoacidosis [0-3]
Diabetic: acidosis without mention of coma
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ketosis without mention of coma 250.2
Diabetes with hyperosmolarity [0-3] Hyperosmolar
(nonketotic) coma
250.3 Diabetes with other coma [0-3] Diabetic coma (with
ketoacidosis); Diabetic hypoglycemic coma Insulin coma
NOS
250.4 Diabetes with renal manifestations [0-3]
250.5 Diabetes with ophthalmic manifestations [0-3]
250.6 Diabetes with neurological manifestations [0-3]
250.7 Diabetes with peripheral circulatory disorders [0-3]
250.8 Diabetes with other specified manifestations [0-3]
Diabetic hypoglycemia NOS; Hypoglycemic shock NOS
250.9 Diabetes with unspecified complication [0-3]
STROKE:
For Stroke codes:
430 Subarachnoid hemorrhage
431 Intracerebral hemorrhage
432.0 Nontraumatic extradural hemorrhage, Nontraumatic epidural
hemorrhage
432.1 Subdural hemorrhage, Subdural hematoma, nontraumatic
432.9 Unspecified intracranial hemorrhage, Intracranial hemorrhage
NOS
433.0, 433.01 Basilar artery
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433.1, 433.10 Carotid artery
433.2, 433.20 Vertebral artery
433.3, 433.30 Multiple and bilateral
433.8, 433.81 Other specified precerebral artery
433.9, 433.91 Unspecified precerebral artery, Precerebral artery NOS
434.00, 434.01 thrombotic
434.10, 434.11 Cerebral embolism
434.91 is general or stroke in evolution, cerebrovascular accident
435.0 Basilar artery syndrome
435.1 Vertebral artery syndrome
435.2 Subclavian steal syndrome
435.3 Vertebrobasilar artery syndrome
435.8 Other specified transient cerebral ischemias
435.9 Unspecified transient cerebral ischemia, progressive
436.0 apoplectic
997.02 Iatrogenic cerebrovascular infarction or hemorrhage
Postoperative stroke
V12.54 Transient ischemic attack (TIA), and cerebral infarction without
residual deficits

HYPERLIPIDEMIA:
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272.2 Hyperlipidemia is defined as high lipids, hypercholesterolemia
and hypercholesterolemia with hyperglycemia endogenous: 272
272.0, 272.1, 272.2, 272.3, 272.4

OBESITY:
278.00 represents obesity and overweight

SMOKER:
305.1 for tabacco use disorder and V15.82 for hx of tabacco use

ALCOHOL ABUSE:
303.9, 303, 303.00, 303.01, 303.02, 303.03, 303.9, 303.90, 303.91
303.92, 303.93 which stands for Chronic alcoholism/Dipsomania
V11.3, V79.1, V11.3 for alcoholism

DEPRESSION:
V79
300.4 Dysthymic disorder
311 depression NOS
Major depresive disorder/recurrent episode: 296.2, 296.20,
296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.3,
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36
Bipolar I disorder, most recent episode (or current) depressed
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296.5, 296.50, 296.5, 296.52, 296.53, 296.54, 296.55,
296.56

Chronic Kidney Disease (CKD):
403 Hypertensive chronic kidney disease [0-1]
403.0 Malignant
403.1 Benign
403.9 Unspecified
585 Chronic kidney disease (CKD):
585.1 Chronic kidney disease, Stage I
585.2 Chronic kidney disease, Stage II (mild)
585.3 Chronic kidney disease, Stage III (moderate)
585.4 Chronic kidney disease, Stage IV (severe)
585.5 Chronic kidney disease, Stage V
585.9 Chronic kidney disease, unspecified

End Stage Renal Disease (ESRD):
585.6 End stage renal disease Chronic kidney disease, stage V
requiring chronic dialysis

Congestive Heart Failure (CHF):
402.0, 402.00, 402.01, 402.1, 402.11, 402.9, 402.90, 402.91
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Hypertensive Heart Disease
404 Hypertensive heart and chronic kidney disease [0-3]
404.0 Malignant
404.1 Benign
404.9 Unspecified
428.0 Congestive heart failure, unspecified
428.1 Left heart failure (Acute edema of lung with heart disease
NOS or heart failure, Acute pulmonary edema with heart
disease NOS or heart failure Cardiac asthma, Left
ventricular failure)
428.9 Heart failure, unspecified Cardiac failure NOS, Heart
failure NOS, Myocardial failure NOS, Weak heart

COPD: Chronic Obstructive Pulmonary Disease:
490 Bronchitis not specified as acute or chronic
491 Chronic Bronchitis
491.0, 491.1, 491.2 Obstructive chronic bronchitis
491.20 Without exacerbation / Emphysema with chronic
bronchitis
491.21 With (acute) exacerbation / Acute
exacerbation of chronic obstructive pulmonary
disease [COPD], Decompensated chronic
obstructive pulmonary disease [COPD],
141

Decompensated chronic obstructive pulmonary
disease [COPD] with exacerbation
491.22 With acute bronchitis
492 Emphysema
492.0 492.8
493 Asthma
493.0 493.00 493.01 493.02
493.1 493.10 493.11 493.12
493.2 493.20 493.21 493.22
493.9 493.90 493.91 493.12
494 Bronchiectasis
494.0 494.1
495 Extrinsic Allergic alveolitis
495.0 495.1 495.2 495.3 495.4 495.5 495.6 495.7
495.8 495.9
496

Chronic Airway Obstruction, not elsewhere
classified
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